,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,45,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
21,47,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
22,49,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
23,51,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
24,53,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
25,55,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
26,57,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
27,59,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
28,61,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
29,63,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
30,65,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
31,67,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
32,69,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
33,71,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
34,73,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
35,75,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
36,77,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
37,79,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
38,81,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
39,99,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
40,101,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
41,103,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
42,105,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
43,107,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
44,109,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
45,113,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
46,115,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
47,119,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
48,121,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
49,123,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
50,125,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
51,131,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
52,133,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
53,135,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
54,137,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
55,139,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
56,141,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
57,143,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
58,145,1,1,,67121,6197,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
59,155,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
60,157,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
61,161,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
62,165,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
63,167,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
64,175,1,1,,67121,6197,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
65,180,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
66,200,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
67,204,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia resistant to methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
68,208,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
69,212,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
70,216,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
71,220,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
72,224,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P335 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
73,228,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
74,232,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
75,236,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  AK4 Lymphoid Leukemia (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
76,238,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Leiomyosarcoma (No. 2) (intraperitoneal) in CAF1 mice,Other,,
77,240,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 4 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
78,242,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
79,246,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1081 Chloroleukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
80,248,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
81,252,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in B6D2F1 (BDF1) mice,Other,,
82,256,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
83,260,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
84,266,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
85,268,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice,Other,,
86,270,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
87,276,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
88,282,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
89,284,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
90,290,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in unknown mice,Other,,
91,296,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
92,300,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in unknown mice,Other,,
93,304,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Mecca (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
94,306,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
95,308,1,1,,67121,6197,Inactive,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to 6-MP and 6-Thioguanine; NSC 755, NSC 752 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
96,312,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  C1498 Myeloid Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
97,316,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
98,318,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P815 Mast Cell Leukemia (Ascitic) (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
99,328,1,1,,67121,6197,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
100,330,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
101,332,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-20 Plasma Cell (subcutaneous) in unknown mice,Other,,
102,336,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
103,338,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
104,340,1,1,,67121,6197,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Reticulum Cell Sarcoma (Kelley Mouse) (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
105,342,1,1,,67121,6197,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
106,377,1,3,,10321885,6197,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
107,421,1,3,,17389082,6197,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
108,421,1,3,,17389083,6197,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
109,426,1,2,,17389082,6197,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
110,426,1,2,,17389083,6197,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
111,427,1,1,,17389082,6197,Active,,,,,Cell Viability - Hek293,Confirmatory,,
112,427,1,1,,17389083,6197,Active,,,,,Cell Viability - Hek293,Confirmatory,,
113,433,1,1,,17389082,6197,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
114,433,1,1,,17389083,6197,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
115,434,1,2,,17389082,6197,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
116,434,1,2,,17389083,6197,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
117,435,1,2,,17389082,6197,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
118,435,1,2,,17389083,6197,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
119,445,3,1,,17389082,6197,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
120,445,3,1,,17389083,6197,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
121,530,1,1,,17389082,6197,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
122,530,1,1,,17389083,6197,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
123,540,1,1,,17389082,6197,Active,,,,,Cell Viability - N2a,Confirmatory,,
124,540,1,1,,17389083,6197,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
125,541,1,1,,17389082,6197,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
126,541,1,1,,17389083,6197,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
127,542,1,1,,17389082,6197,Inconclusive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
128,542,1,1,,17389083,6197,Active,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
129,543,1,1,,17389082,6197,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
130,543,1,1,,17389083,6197,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
131,544,2,1,,17389082,6197,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
132,544,2,1,,17389083,6197,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
133,545,1,1,,17389082,6197,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
134,545,1,1,,17389083,6197,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
135,546,1,1,,17389082,6197,Active,,,,,Cell Viability - Mesenchymal,Confirmatory,,
136,546,1,1,,17389083,6197,Active,,,,,Cell Viability - Mesenchymal,Confirmatory,,
137,584,1,3,,17389082,6197,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
138,584,1,3,,17389083,6197,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
139,585,1,4,,17389082,6197,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
140,585,1,4,,17389083,6197,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
141,595,1,3,,17389082,6197,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
142,595,1,3,,17389083,6197,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
143,596,1,2,,17389082,6197,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
144,596,1,2,,17389083,6197,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
145,603,1,2,,17389082,6197,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
146,603,1,2,,17389083,6197,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
147,605,1,2,,17389082,6197,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
148,605,1,2,,17389083,6197,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
149,654,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
150,654,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
151,655,1,1,,17389082,6197,Inconclusive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
152,655,1,1,,17389083,6197,Inconclusive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
153,656,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
154,656,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
155,657,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
156,657,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
157,658,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
158,658,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
159,659,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
160,659,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
161,660,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
162,660,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
163,661,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
164,661,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
165,662,1,1,,17389082,6197,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
166,662,1,1,,17389083,6197,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
167,663,1,1,,17389082,6197,Active,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
168,663,1,1,,17389083,6197,Active,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
169,664,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
170,664,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
171,665,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
172,665,1,1,,17389083,6197,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
173,666,1,1,,17389082,6197,Inconclusive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
174,666,1,1,,17389083,6197,Inconclusive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
175,667,1,1,,17389082,6197,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
176,667,1,1,,17389083,6197,Inconclusive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
177,875,1,2,,17389082,6197,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
178,875,1,2,,17389083,6197,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
179,880,2,1,,17389082,6197,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
180,880,2,1,,17389082,6197,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
181,880,2,1,,17389083,6197,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
182,880,2,1,,17389083,6197,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
183,880,2,1,,50104677,6197,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
184,880,2,1,,50104677,6197,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
185,881,2,2,,17389082,6197,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
186,881,2,2,,17389083,6197,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
187,884,1,2,,17389082,6197,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
188,884,1,2,,17389083,6197,Inconclusive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
189,885,1,2,,17389082,6197,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
190,885,1,2,,17389083,6197,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
191,886,1,2,,17389082,6197,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
192,886,1,2,,17389082,6197,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
193,886,1,2,,17389083,6197,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
194,886,1,2,,17389083,6197,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
195,887,1,2,,17389082,6197,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
196,887,1,2,,17389083,6197,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
197,889,1,3,,17389082,6197,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
198,889,1,3,,17389083,6197,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
199,892,1,2,,17389082,6197,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
200,892,1,2,,17389083,6197,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
201,893,1,2,,17389082,6197,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
202,893,1,2,,17389082,6197,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
203,893,1,2,,17389083,6197,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
204,893,1,2,,17389083,6197,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
205,894,2,1,,17389082,6197,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
206,894,2,1,,17389083,6197,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
207,894,2,1,,50104677,6197,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
208,900,1,3,,17389082,6197,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
209,900,1,3,,17389083,6197,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
210,901,1,2,,17389083,6197,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
211,902,1,2,,17389082,6197,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
212,902,1,2,,17389083,6197,Inconclusive,120407068.0,7157.0,0.2512,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
213,912,1,2,,17389082,6197,Inconclusive,21392848.0,,0.1259,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
214,912,1,2,,17389083,6197,Inconclusive,21392848.0,,0.2512,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
215,921,1,2,,17389082,6197,Active,,,1.2589,Potency,Cell Viability - LYMP2-001,Confirmatory,,
216,921,1,2,,17389083,6197,Active,,,1.5849,Potency,Cell Viability - LYMP2-001,Confirmatory,,
217,923,1,2,,17389082,6197,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
218,923,1,2,,17389083,6197,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
219,924,1,2,,17389082,6197,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
220,924,1,2,,17389083,6197,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
221,925,1,2,,17389082,6197,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
222,925,1,2,,17389083,6197,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
223,926,1,2,,17389082,6197,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
224,926,1,2,,17389083,6197,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
225,938,1,2,,17389082,6197,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
226,938,1,2,,17389083,6197,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
227,940,1,2,,26612307,6197,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
228,946,1,2,,17389082,6197,Inconclusive,,,10.0,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
229,946,1,2,,17389083,6197,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
230,947,1,2,,17389082,6197,Inconclusive,,,2.5119,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
231,947,1,2,,17389083,6197,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
232,948,1,2,,17389082,6197,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
233,948,1,2,,17389083,6197,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
234,955,1,2,,17389082,6197,Inconclusive,,,1.0,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
235,955,1,2,,17389083,6197,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
236,960,1,2,,17389082,6197,Active,,,15.8489,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
237,960,1,2,,17389083,6197,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
238,961,1,2,,17389082,6197,Active,,,50.1187,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
239,961,1,2,,17389083,6197,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
240,962,1,2,,17389082,6197,Inconclusive,,,0.3162,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
241,962,1,2,,17389083,6197,Inconclusive,,,0.2512,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
242,963,1,2,,17389082,6197,Inconclusive,,,2.5119,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
243,963,1,2,,17389083,6197,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
244,964,1,2,,17389082,6197,Active,,,1.9953,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
245,964,1,2,,17389083,6197,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
246,965,1,2,,17389082,6197,Inconclusive,,,0.3981,Potency,Cell Viability - LYMP2-003,Confirmatory,,
247,965,1,2,,17389083,6197,Inconclusive,,,0.2512,Potency,Cell Viability - LYMP2-003,Confirmatory,,
248,966,1,2,,17389082,6197,Inconclusive,,,0.1995,Potency,Cell Viability - LYMP2-004,Confirmatory,,
249,966,1,2,,17389083,6197,Inconclusive,,,0.5012,Potency,Cell Viability - LYMP2-004,Confirmatory,,
250,967,1,2,,17389082,6197,Inconclusive,,,0.3981,Potency,Cell Viability - LYMP2-005,Confirmatory,,
251,967,1,2,,17389083,6197,Active,,,0.3162,Potency,Cell Viability - LYMP2-005,Confirmatory,,
252,968,1,2,,17389082,6197,Inconclusive,,,0.631,Potency,Cell Viability - LYMP2-009,Confirmatory,,
253,968,1,2,,17389083,6197,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP2-009,Confirmatory,,
254,969,1,2,,17389082,6197,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP2-011,Confirmatory,,
255,969,1,2,,17389083,6197,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP2-011,Confirmatory,,
256,970,1,2,,17389082,6197,Active,,,1.9953,Potency,Cell Viability - LYMP2-013,Confirmatory,,
257,970,1,2,,17389083,6197,Active,,,1.9953,Potency,Cell Viability - LYMP2-013,Confirmatory,,
258,971,1,2,,17389082,6197,Active,,,1.9953,Potency,Cell Viability - LYMP2-015,Confirmatory,,
259,971,1,2,,17389083,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-015,Confirmatory,,
260,972,1,2,,17389082,6197,Active,,,1.5849,Potency,Cell Viability - LYMP2-017,Confirmatory,,
261,972,1,2,,17389083,6197,Active,,,1.5849,Potency,Cell Viability - LYMP2-017,Confirmatory,,
262,973,1,2,,17389082,6197,Inconclusive,,,0.3981,Potency,Cell Viability - LYMP2-019,Confirmatory,,
263,973,1,2,,17389083,6197,Inconclusive,,,0.3981,Potency,Cell Viability - LYMP2-019,Confirmatory,,
264,974,1,2,,17389082,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-021,Confirmatory,,
265,974,1,2,,17389083,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-021,Confirmatory,,
266,975,1,2,,17389082,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-023,Confirmatory,,
267,975,1,2,,17389083,6197,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP2-023,Confirmatory,,
268,976,1,2,,17389082,6197,Inconclusive,,,3.1623,Potency,Cell Viability - LYMP2-025,Confirmatory,,
269,976,1,2,,17389083,6197,Inconclusive,,,2.5119,Potency,Cell Viability - LYMP2-025,Confirmatory,,
270,977,1,2,,17389082,6197,Inconclusive,,,0.7943,Potency,Cell Viability - LYMP2-002,Confirmatory,,
271,977,1,2,,17389083,6197,Inconclusive,,,0.7943,Potency,Cell Viability - LYMP2-002,Confirmatory,,
272,978,1,2,,17389082,6197,Active,,,2.5119,Potency,Cell Viability - LYMP2-006,Confirmatory,,
273,978,1,2,,17389083,6197,Inconclusive,,,1.9953,Potency,Cell Viability - LYMP2-006,Confirmatory,,
274,979,1,2,,17389082,6197,Inconclusive,,,0.3981,Potency,Cell Viability - LYMP2-007,Confirmatory,,
275,979,1,2,,17389083,6197,Inconclusive,,,0.5012,Potency,Cell Viability - LYMP2-007,Confirmatory,,
276,980,1,2,,17389082,6197,Inconclusive,,,0.631,Potency,Cell Viability - LYMP2-008,Confirmatory,,
277,980,1,2,,17389083,6197,Inconclusive,,,0.7943,Potency,Cell Viability - LYMP2-008,Confirmatory,,
278,981,1,2,,17389082,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-010,Confirmatory,,
279,981,1,2,,17389083,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-010,Confirmatory,,
280,982,1,2,,17389082,6197,Active,,,0.631,Potency,Cell Viability - LYMP2-012,Confirmatory,,
281,982,1,2,,17389083,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-012,Confirmatory,,
282,983,1,2,,17389082,6197,Inconclusive,,,0.5012,Potency,Cell Viability - LYMP2-014,Confirmatory,,
283,983,1,2,,17389083,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-014,Confirmatory,,
284,984,1,2,,17389082,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-016,Confirmatory,,
285,984,1,2,,17389083,6197,Inconclusive,,,0.7943,Potency,Cell Viability - LYMP2-016,Confirmatory,,
286,985,1,2,,17389082,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-018,Confirmatory,,
287,985,1,2,,17389083,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-018,Confirmatory,,
288,986,1,2,,17389082,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-020,Confirmatory,,
289,986,1,2,,17389083,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-020,Confirmatory,,
290,987,1,2,,17389082,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-022,Confirmatory,,
291,987,1,2,,17389083,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-022,Confirmatory,,
292,988,1,2,,17389082,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-024,Confirmatory,,
293,988,1,2,,17389083,6197,Active,,,0.7943,Potency,Cell Viability - LYMP2-024,Confirmatory,,
294,989,1,2,,17389082,6197,Active,,,1.0,Potency,Cell Viability - LYMP2-026,Confirmatory,,
295,989,1,2,,17389083,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP2-026,Confirmatory,,
296,993,1,2,,17389082,6197,Inconclusive,,,1.0,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
297,993,1,2,,17389083,6197,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
298,994,1,2,,17389082,6197,Active,,,1.2589,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
299,994,1,2,,17389083,6197,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
300,995,1,2,,17389082,6197,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
301,995,1,2,,17389083,6197,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
302,1030,2,1,,17389082,6197,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
303,1030,2,1,,17389083,6197,Inconclusive,30582681.0,216.0,31.6228,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
304,1030,2,1,,50104677,6197,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
305,1332,1,1,,49698641,6197,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
306,1379,1,2,,50104677,6197,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
307,1422,1,1,,26612307,6197,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
308,1452,1,1,,17389082,6197,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
309,1452,1,1,,17389083,6197,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
310,1454,1,1,,50104677,6197,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
311,1457,1,1,,17389082,6197,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
312,1457,1,1,,17389083,6197,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
313,1457,1,1,,50104677,6197,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
314,1458,1,1,,17389082,6197,Inactive,10937869.0,6607.0,2.8184,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
315,1458,1,1,,17389083,6197,Inactive,10937869.0,6607.0,1.7783,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
316,1460,1,3,,50104677,6197,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
317,1463,1,1,,50104677,6197,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
318,1467,1,3,,50104677,6197,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
319,1468,1,1,,50104677,6197,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
320,1469,1,1,,17389082,6197,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
321,1469,1,1,,17389083,6197,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
322,1469,1,1,,26752000,6197,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
323,1469,1,1,,50104677,6197,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
324,1471,2,1,,17389082,6197,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
325,1471,2,1,,17389083,6197,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
326,1471,2,1,,50104677,6197,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
327,1476,2,1,,17389082,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
328,1476,2,1,,17389083,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
329,1476,2,1,,50104677,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
330,1477,1,1,,17389082,6197,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
331,1477,1,1,,17389083,6197,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
332,1477,1,1,,50104677,6197,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
333,1478,2,1,,17389082,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
334,1478,2,1,,17389083,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
335,1478,2,1,,50104677,6197,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
336,1479,1,2,,17389082,6197,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
337,1479,1,2,,17389083,6197,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
338,1479,1,2,,26752000,6197,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
339,1479,1,2,,50104677,6197,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
340,1490,2,1,,50104677,6197,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
341,1519,1,3,,50104677,6197,Inconclusive,,,0.5623,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
342,1576,1,1,,57244122,6197,Inactive,,,,,DSSTox (KIERBL) EPA Estrogen Receptor Ki Binding Study (Laws et al.) Database,Other,,
343,1580,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
344,1581,1,1,,8149831,6197,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
345,1582,1,1,,8149831,6197,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
346,1583,1,1,,8149831,6197,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
347,1584,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
348,1585,1,1,,8149831,6197,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
349,1586,1,1,,8149831,6197,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
350,1587,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
351,1588,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
352,1589,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
353,1590,1,1,,8149831,6197,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
354,1593,1,1,,8149831,6197,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
355,1594,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
356,1595,1,1,,8149831,6197,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
357,1596,1,1,,8149831,6197,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
358,1597,1,1,,8149831,6197,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
359,1598,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
360,1599,1,1,,8149831,6197,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
361,1600,1,1,,8149831,6197,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
362,1601,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
363,1602,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
364,1603,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
365,1604,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
366,1605,1,1,,8149831,6197,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
367,1606,1,1,,8149831,6197,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
368,1607,1,1,,8149831,6197,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
369,1608,1,1,,8149831,6197,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
370,1609,1,1,,8149831,6197,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
371,1610,1,1,,8149831,6197,Active,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
372,1611,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
373,1612,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
374,1613,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
375,1614,1,1,,8149831,6197,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
376,1616,1,1,,8149831,6197,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
377,1766,1,1,,50104677,6197,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
378,1766,1,1,,50104677,6197,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
379,1768,1,1,,50104677,6197,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
380,1768,1,1,,50104677,6197,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
381,1865,1,1,,50104677,6197,Inconclusive,,,2.8184,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
382,1948,1,1,,17389082,6197,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
383,1948,1,1,,17389083,6197,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
384,1948,1,1,,50104677,6197,Inactive,,,0.0316,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
385,1987,1,2,,56463698,6197,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
386,2016,1,3,,56463698,6197,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
387,2023,1,3,,56463698,6197,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
388,2025,1,3,,56463698,6197,Active,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
389,2029,1,3,,56463698,6197,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
390,2052,2,1,,56463698,6197,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
391,2057,1,2,,56463698,6197,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
392,2066,1,4,,56463698,6197,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
393,2099,1,1,,56463698,6197,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
394,2101,1,1,,17389082,6197,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
395,2101,1,1,,17389083,6197,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
396,2101,1,1,,50104677,6197,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
397,2107,1,1,,17389082,6197,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
398,2107,1,1,,17389083,6197,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
399,2107,1,1,,50104677,6197,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
400,2112,1,1,,17389082,6197,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
401,2112,1,1,,17389083,6197,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
402,2112,1,1,,50104677,6197,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
403,2120,1,1,,17389082,6197,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
404,2120,1,1,,17389083,6197,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
405,2129,1,2,,56463698,6197,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
406,2130,1,3,,56463698,6197,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
407,2147,1,1,,50104677,6197,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
408,2174,1,3,,56463698,6197,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
409,2177,1,3,,56463698,6197,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
410,2234,1,2,,56463698,6197,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
411,2235,1,2,,56463698,6197,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
412,2240,1,1,,85788478,6197,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
413,2241,1,1,,85788478,6197,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
414,2275,1,1,,85788478,6197,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
415,2280,2,3,,56463698,6197,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
416,2297,1,2,,85860295,6197,Unspecified,,,,,Inhibition Frequency Index,Other,,
417,2300,1,3,,56463698,6197,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
418,2302,1,2,,85860295,6197,Active,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
419,2303,1,2,,85860295,6197,Inactive,,,,,Inhibition of HepG2 cell line,Screening,,
420,2304,1,2,,85860295,6197,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
421,2305,1,2,,85860295,6197,Unspecified,,,0.53,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
422,2306,1,2,,85860295,6197,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
423,2313,1,1,,85788478,6197,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
424,2322,1,1,,85788478,6197,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
425,2330,1,1,,85788478,6197,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
426,2380,1,2,,56463698,6197,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
427,2391,1,1,,56463698,6197,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
428,2435,1,2,,56463698,6197,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
429,2445,1,2,,56463698,6197,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
430,2451,1,2,,50104677,6197,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
431,2462,1,1,,56463698,6197,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
432,2462,1,1,,56463698,6197,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
433,2472,1,2,,50104677,6197,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
434,2517,2,1,,17389082,6197,Inactive,6980812.0,,0.3981,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
435,2517,2,1,,17389083,6197,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
436,2517,2,1,,50104677,6197,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
437,2517,2,1,,56463698,6197,Inactive,6980812.0,,75.193,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
438,2517,2,1,,144207129,6197,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
439,2520,1,4,,56463698,6197,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
440,2521,1,3,,56463698,6197,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
441,2524,1,2,,56463698,6197,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
442,2528,1,2,,50104677,6197,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
443,2540,1,2,,56463698,6197,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
444,2544,1,2,,56463698,6197,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
445,2546,1,1,,17389082,6197,Active,188536040.0,19885.0,0.0089,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
446,2546,1,1,,17389083,6197,Inconclusive,188536040.0,19885.0,10.0,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
447,2546,1,1,,50104677,6197,Inconclusive,188536040.0,19885.0,0.0018,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
448,2549,1,1,,17389082,6197,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
449,2549,1,1,,17389083,6197,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
450,2549,1,1,,50104677,6197,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
451,2551,1,1,,17389082,6197,Active,188536040.0,19885.0,0.0794,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
452,2551,1,1,,17389083,6197,Inconclusive,188536040.0,19885.0,0.0631,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
453,2551,1,1,,50104677,6197,Active,188536040.0,19885.0,0.3162,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
454,2557,1,3,,56463698,6197,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
455,2599,1,2,,56463698,6197,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
456,2606,1,2,,56463698,6197,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
457,2621,1,3,,56463698,6197,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically LAP4 Second Cherry Pick Compounds,Screening,,
458,2622,1,3,,56463698,6197,Active,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically MEP2 Second Cherry Pick Compounds,Screening,,
459,2623,1,3,,56463698,6197,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically RPL19A Second Cherry Pick Compounds,Screening,,
460,2624,1,3,,56463698,6197,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically CIT2 Second Cherry Pick Compounds,Screening,,
461,2629,1,1,,56463698,6197,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
462,2643,1,4,,56463698,6197,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically AGP1 Second Cherry Pick Compounds,Screening,,
463,2650,2,1,,56463698,6197,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
464,2661,1,1,,56463698,6197,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
465,2676,1,2,,56463698,6197,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
466,2685,1,1,,56463698,6197,Inconclusive,,,0.3663,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
467,2690,1,2,,56463698,6197,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
468,2716,1,1,,56463698,6197,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
469,2717,1,2,,56463698,6197,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
470,2718,1,1,,56463698,6197,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
471,2740,1,2,,56463698,6197,Active,536029.0,,0.644,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically RPL19A based on MLPCN hits,Confirmatory,,
472,2742,1,2,,56463698,6197,Inactive,1302091.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically MEP2 based on MLPCN hits,Confirmatory,,
473,2743,1,2,,56463698,6197,Inactive,85666113.0,850333.0,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically AGP1 based on MLPCN hits,Confirmatory,,
474,2744,1,2,,56463698,6197,Inactive,171229.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically CIT2 based on MLPCN hits,Confirmatory,,
475,2745,1,1,,56463698,6197,Inactive,486173.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically LAP4 based on MLPCN hits,Confirmatory,,
476,2751,2,2,,56463698,6197,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
477,2757,1,2,,56463698,6197,Inactive,,,,,Test compound autofluorescence in Saccharomyes cerevisiae specifically s288c,Other,,
478,2796,1,4,,56463698,6197,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
479,2797,1,2,,56463698,6197,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
480,2805,2,2,,56463698,6197,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
481,2806,2,2,,56463698,6197,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
482,2825,1,2,,56463698,6197,Active,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
483,8448,6,2,,103348651,6197,Active,,,0.2,IC50,Tested in vitro for anticancer activity against 9L cells,Confirmatory,10072683.0,
484,41737,7,1,,103348651,6197,Active,,,,,Minimum inhibitory concentration against Benjaminiella poitrassi,Other,14998344.0,
485,47311,6,2,,103348651,6197,Active,,,0.08,IC50,"Cytotoxicity was determined in CEM cells, relative to RVT",Confirmatory,15081000.0,
486,47449,6,2,,103348651,6197,Active,,,0.12,IC50,Tested in vitro for anticancer activity against CEM cells,Confirmatory,10072683.0,
487,48767,7,1,,103348651,6197,Active,,,,,Minimum inhibitory concentration against Candida albicans,Other,14998344.0,
488,54722,6,2,,103348651,6197,Unspecified,,,200.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of human Cyclophilin 18 (Conc=2 nM),Confirmatory,10479292.0,
489,69105,9,2,,103348651,6197,Active,,,3.6,IC50,Compound was evaluated for its inhibitory effect on human FK506 binding protein 12 by means of protease-coupled PPIase assay,Confirmatory,10479292.0,
490,69109,9,2,,103348651,6197,Active,,,3.4,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of human FK506 binding protein 12 (Conc=14 nM) of FKBPs family,Confirmatory,10479292.0,
491,69262,9,2,,103348651,6197,Unspecified,,,76.2,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Photobacterium sp. FK506 binding protein 22 (Conc=41 nM) of FKBPs family,Confirmatory,10479292.0,
492,69263,6,4,,103348651,6197,Unspecified,,,124.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Legionella pneumophilia FK506 binding protein 25 (Conc=40 nM) of FKBPs family,Confirmatory,10479292.0,
493,69264,6,2,,103348651,6197,Active,,,10.3,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Escherichia coli FK506 binding protein 26 (Conc=1 uM) of FKBPs family,Confirmatory,10479292.0,
494,69265,9,2,,103348651,6197,Active,,,24.2,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of rabbit FK506 binding protein 52 (Conc=52 nM) of FKBPs family,Confirmatory,10479292.0,
495,86696,6,2,,103348651,6197,Active,,,2.5,IC50,Tested in vitro for anticancer activity against HepG2 cells,Confirmatory,10072683.0,
496,93962,6,2,,103348651,6197,Unspecified,,,,,"Cytotoxicity against mouse K-562 leukemic cell line, by means of standard proliferation assay",Other,10479292.0,
497,94963,6,2,,103348651,6197,Active,,,0.93,IC50,Inhibitory concentration against Human Jurkat T cells,Confirmatory,10212121.0,
498,95084,7,1,,103348651,6197,Active,,,,,Inhibitory concentration against Human Jurkat T cells,Other,10212121.0,
499,95087,3,4,,103348651,6197,Unspecified,,,,,IC80 concentrations of the compounds were used in determining the inhibition of RNA synthesis using Jurkat T cells.,Other,10212121.0,
500,95088,3,4,,103348651,6197,Unspecified,,,,,IC80 concentrations of the compounds were used in determining the inhibition of protein synthesis using Jurkat T cells.,Other,10212121.0,
501,95247,6,2,,103348651,6197,Unspecified,,,,,"Cytotoxicity against mouse L-929 fibroblast cell line, by means of standard proliferation assay",Other,10479292.0,
502,100403,6,2,,103348651,6197,Active,,,1.2,IC50,Tested in vitro for anticancer activity against LNCaP cells,Confirmatory,10072683.0,
503,102615,6,2,,103348651,6197,Active,,,1.5,IC50,Tested in vitro for anticancer activity against MCF-7 cells,Confirmatory,10072683.0,
504,152793,8,3,,103348651,6197,Inconclusive,,,,,The compound was tested in vitro for anti HIV-1 activity against PBM cells; Not determined,Other,10072683.0,
505,152794,6,3,,103348651,6197,Active,,,2.1,IC50,Tested in vitro for cytotoxicity against PBM cells,Confirmatory,10072683.0,
506,155106,8,2,,103348651,6197,Inconclusive,,,,,"The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined",Other,15081000.0,
507,155120,5,2,,103348651,6197,Inconclusive,,,,,"The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined",Other,15081000.0,
508,155299,6,2,,103348651,6197,Active,,,0.46,IC50,"Cytotoxicity was determined in PBM cells, relative to RVT",Confirmatory,15081000.0,
509,155746,6,4,,103348651,6197,Unspecified,,,187.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Escherichia coli parvulin (Conc=4 nM) of Parvulins sfamily,Confirmatory,10479292.0,
510,156334,6,2,,103348651,6197,Active,,,3.5,IC50,Tested in vitro for anticancer activity against PC-3 cells,Confirmatory,10072683.0,
511,157094,6,4,,103348651,6197,Unspecified,,,200.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of human Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Conc=4 nM) of Parvulins family,Confirmatory,10479292.0,
512,201986,6,2,,103348651,6197,Active,,,1.0,IC50,Tested in vitro for anticancer activity against SK-MEL-28 cells,Confirmatory,10072683.0,
513,202327,6,2,,103348651,6197,Active,,,2.7,IC50,Tested in vitro for anticancer activity against SK-MES-1 cells,Confirmatory,10072683.0,
514,205130,6,2,,103348651,6197,Unspecified,,,200.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Escherichia coli SlyD (Conc=2 uM) of FKBPs family,Confirmatory,10479292.0,
515,214623,6,2,,103348651,6197,Unspecified,,,200.0,Ki,Inhibition constant(Ki) for inhibition of PPIase activity of Escherichia coli trigger factor (Conc=12 nM) of FKBPs family,Confirmatory,10479292.0,
516,216188,6,2,,103348651,6197,Active,,,1.2,IC50,Tested in vitro for cytotoxicity against Vero cells,Confirmatory,10072683.0,
517,217732,6,2,,103348651,6197,Active,,,0.53,IC50,"Cytotoxicity was determined in Vero cells, relative to RVT",Confirmatory,15081000.0,
518,220090,7,1,,103348651,6197,Active,,,,,Minimum inhibitory concentration against Yarrowia lipolytica,Other,14998344.0,
519,221820,6,2,,103348651,6197,Active,,,0.93,IC50,Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours,Confirmatory,11052798.0,
520,221821,7,1,,103348651,6197,Active,,,,,Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours,Other,11052798.0,
521,221823,3,5,,103348651,6197,Unspecified,,,,,Apoptotic index calculated using human Jurkat T cells,Other,11052798.0,
522,221824,3,4,,103348651,6197,Unspecified,,,,,Inhibition of RNA synthesis was evaluated on human Jurkat T-cells after 8 hours.,Other,11052798.0,
523,221825,3,4,,103348651,6197,Unspecified,,,,,Inhibition of protein synthesis was evaluated on human Jurkat T-cells after 8 hours.,Other,11052798.0,
524,224494,6,2,,103348651,6197,Active,,,5.0,IC50,In vitro inhibition of protein synthesis in tobacco mosaic virus mRNA-encoded proteins in rabbit reticulocyte lysate,Confirmatory,11063617.0,
525,278576,7,2,,103348651,6197,Active,,,0.15,IC50,Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs,Confirmatory,17060533.0,
526,278577,7,2,,103348651,6197,Active,,,0.1,IC50,Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs,Confirmatory,17060533.0,
527,278586,3,4,,103348651,6197,Inactive,,,,,Reduced apicoplast DNA/nuclear DNA ratio in Plasmodium falciparum FCK2 at 100 nM after 72 hrs by competitive PCR,Other,17060533.0,
528,289222,6,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae in synthetic defined media without leucine,Other,17588934.0,
529,301255,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 1 at 40 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
530,301256,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 1 at 60 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
531,301257,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 1 at 100 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
532,301258,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 2 at 40 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
533,301259,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 2 at 60 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
534,301260,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 2 at 100 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
535,301261,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 1 at 40 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
536,301262,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 1 at 60 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
537,301263,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 1 at 100 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
538,301264,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 2 at 40 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
539,301265,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 2 at 60 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
540,301266,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 2 at 100 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
541,301267,3,3,,103348651,6197,Inactive,,,,,Antifungal activity against Mucor at 40 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
542,301268,3,3,,103348651,6197,Inactive,,,,,Antifungal activity against Mucor at 60 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
543,301269,3,3,,103348651,6197,Inactive,,,,,Antifungal activity against Mucor at 100 ug/disc after 24 hrs by disc diffusion method,Other,17765545.0,
544,301270,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 1 after 24 hrs by disc diffusion method,Other,17765545.0,
545,301271,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 2 after 24 hrs by disc diffusion method,Other,17765545.0,
546,301272,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 1 after 24 hrs by disc diffusion method,Other,17765545.0,
547,301273,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum 2 after 24 hrs by disc diffusion method,Other,17765545.0,
548,301274,5,2,,103348651,6197,Inconclusive,,,,,Antifungal activity against Mucor at after 24 hrs by disc diffusion method,Other,17765545.0,
549,311935,3,4,,103348651,6197,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
550,325035,6,4,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Candida albicans SC5314 after 24 hrs by broth macrodilution method,Other,17325226.0,
551,325036,6,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Candida albicans P5 after 24 hrs by broth macrodilution method,Other,17325226.0,
552,325037,6,4,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Candida albicans SC5314 after 48 hrs by broth macrodilution method,Other,17325226.0,
553,325038,6,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Candida albicans P5 after 48 hrs by broth macrodilution method,Other,17325226.0,
554,329355,6,1,,103348651,6197,Active,,,,,Cytotoxicity against human HeLa cells after 24 hrs,Other,18394884.0,
555,335821,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus niger UPCC 3701 assessed as clearing zone at 30 ug after 48 hrs,Other,12193012.0,
556,335828,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus niger UPCC 3701 assessed as antimicrobial index at 30 ug after 48 hrs,Other,12193012.0,
557,344865,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 10 uM by MTT assay,Other,18930401.0,
558,344866,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 25 uM by MTT assay,Other,18930401.0,
559,344867,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 50 uM by MTT assay,Other,18930401.0,
560,344868,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 10 uM by MTT assay,Other,18930401.0,
561,344869,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 25 uM by MTT assay,Other,18930401.0,
562,344870,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 50 uM by MTT assay,Other,18930401.0,
563,354538,3,4,,103348651,6197,Inactive,,,,,Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Other,8988604.0,
564,354542,3,4,,103348651,6197,Inactive,,,,,Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs,Other,8988604.0,
565,354543,3,4,,103348651,6197,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
566,355374,3,3,,103348651,6197,Active,,,,,Antifungal activity against Ustilago violacea at 60 ug by agar diffusion assay,Other,9358636.0,
567,355375,6,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Mycotypha microspora at 60 ug by agar diffusion assay,Other,9358636.0,
568,355376,6,2,,103348651,6197,Unspecified,,,,,Antifungal activity Eurotium repens at 60 ug by agar diffusion assay,Other,9358636.0,
569,355377,6,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 60 ug by agar diffusion assay,Other,9358636.0,
570,362510,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 10 uM after 48 hrs by MTT assay,Other,18680358.0,
571,362511,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 25 uM after 48 hrs by MTT assay,Other,18680358.0,
572,362512,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human A431 cells at 50 uM after 48 hrs by MTT assay,Other,18680358.0,
573,362513,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 10 uM after 48 hrs by MTT assay,Other,18680358.0,
574,362514,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 25 uM after 48 hrs by MTT assay,Other,18680358.0,
575,362515,3,4,,103348651,6197,Unspecified,,,,,Antiproliferative activity against human SW480 cells at 50 uM after 48 hrs by MTT assay,Other,18680358.0,
576,362760,8,1,,103348651,6197,Active,,,0.912,IC50,Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay,Confirmatory,18771242.0,
577,383010,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Helminthosporium species at 100 ppm after 96 hrs,Other,17555846.0,
578,383011,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Helminthosporium species at 500 ppm after 96 hrs,Other,17555846.0,
579,383012,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Helminthosporium species at 1000 ppm after 96 hrs,Other,17555846.0,
580,383013,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 100 ppm after 96 hrs,Other,17555846.0,
581,383014,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 500 ppm after 96 hrs,Other,17555846.0,
582,383015,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum at 1000 ppm after 96 hrs,Other,17555846.0,
583,383016,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Alternaria alternata at 100 ppm after 96 hrs,Other,17555846.0,
584,383017,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Alternaria alternata at 500 ppm after 96 hrs,Other,17555846.0,
585,383018,3,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Alternaria alternata at 1000 ppm after 96 hrs,Other,17555846.0,
586,383756,11,1,,103348651,6197,Unspecified,,,,IC50,Cytotoxicity against human A549 cells,Confirmatory,17618015.0,
587,384024,6,3,,103348651,6197,Unspecified,,,,,Cytotoxicity against human H116 cells,Other,17618015.0,
588,384025,6,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against human PSN1 cells,Other,17618015.0,
589,384026,6,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against human T98G cells,Other,17618015.0,
590,384027,6,3,,103348651,6197,Unspecified,,,,,Cytotoxicity against human SKBR3 cells,Other,17618015.0,
591,386133,3,3,,103348651,6197,Inactive,,,,,Induction of GFP tagged PagsA expression in Aspergillus niger JvD1.1 at 104.2 ug/mL by fluorescence microscopy,Other,17804411.0,
592,386134,3,3,,103348651,6197,Inactive,,,,,Induction of GFP tagged PagsA-H2B expression in Aspergillus niger RD6.47 at 104.2 ug/mL by fluorescence microscopy,Other,17804411.0,
593,386135,3,3,,103348651,6197,Active,,,,,Antifungal activity against Aspergillus niger JvD1.1 at 104.2 ug/mL by microtiter plate,Other,17804411.0,
594,386136,3,3,,103348651,6197,Active,,,,,Antifungal activity against Aspergillus niger RD6.47 at 104.2 ug/mL by microtiter plate,Other,17804411.0,
595,386537,5,2,,103348651,6197,Unspecified,,,100.0,GI50,Cytotoxicity against human NCI-H23 cells,Confirmatory,18243714.0,
596,386538,5,2,,103348651,6197,Unspecified,,,100.0,GI50,Cytotoxicity against human NCI-H522 cells,Confirmatory,18243714.0,
597,386539,5,2,,103348651,6197,Unspecified,,,100.0,GI50,Cytotoxicity against human A549 cells,Confirmatory,18243714.0,
598,402323,3,10,,103348651,6197,Active,2498017.0,3091.0,,,"Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting",Other,15974627.0,
599,402324,3,10,,103348651,6197,Active,2498017.0,3091.0,,,"Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting",Other,15974627.0,
600,402325,3,10,,103348651,6197,Inactive,114163.0,405.0,,,Inhibition of hypoxia-induced HIF1beta activation in human T47D cells at 10 uM after 4 hrs by Western blotting,Other,15974627.0,
601,402326,3,10,,103348651,6197,Inactive,114163.0,405.0,,,Inhibition of hypoxia-induced HIF1beta activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting,Other,15974627.0,
602,402330,3,4,,103348651,6197,Active,,,,,Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay,Other,15974627.0,
603,402334,3,4,,103348651,6197,Active,,,,,"Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay",Other,15974627.0,
604,402338,3,4,,103348651,6197,Active,,,,,Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA,Other,15974627.0,
605,402339,3,10,,103348651,6197,Active,2498017.0,3091.0,,,Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting,Other,15974627.0,
606,402340,3,10,,103348651,6197,Active,2498017.0,3091.0,,,Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting,Other,15974627.0,
607,402342,4,4,,103348651,6197,Active,,,0.036000000000000004,IC50,Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay,Confirmatory,15974627.0,
608,402343,3,3,,103348651,6197,Active,,,,,Inhibition of luciferase expression in TNT T7 coupled reticulocyte lysate system at 10 uM,Other,15974627.0,
609,402346,3,4,,103348651,6197,Unspecified,,,,,Inhibition of hypoxia-induced secreted VEGF expression in human T47D cells at 10 uM after 16 by ELISA relative to normoxic control,Other,15974627.0,
610,402348,3,4,,103348651,6197,Inactive,,,,,Inhibition of hypoxia-induced secreted VEGF expression in human T47D cells at 0.3 uM after 16 by ELISA,Other,15974627.0,
611,403071,8,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Septoria nodorum after 48 hrs by agar-based microtiter plate assay,Other,16124766.0,
612,403073,3,3,,103348651,6197,Inactive,,,,,Antifungal activity against Candida albicans up to 50 mg/ml after 48 hrs by agar-based microtiter plate assay,Other,16124766.0,
613,406146,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Escherichia coli by agar diffusion method,Other,18510362.0,
614,406147,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Bacillus megaterium by agar diffusion method,Other,18510362.0,
615,406148,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Microbotryum violaceum by agar diffusion method,Other,18510362.0,
616,406149,3,4,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Chlorella fusca by agar diffusion method,Other,18510362.0,
617,409942,11,2,,103348651,6197,Inactive,113978.0,4128.0,,IC50,Inhibition of human recombinant MAOA by fluorimetric method,Confirmatory,18834112.0,
618,409943,11,2,,103348651,6197,Inactive,113980.0,4129.0,,IC50,Inhibition of human recombinant MAOB by fluorimetric method,Confirmatory,18834112.0,
619,425713,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 100 uM after 7 days,Other,17875991.0,
620,425714,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 200 uM after 7 days,Other,17875991.0,
621,425715,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 500 uM after 7 days,Other,17875991.0,
622,425720,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 100 uM after 24 hrs by LDH release assay,Other,17875991.0,
623,425721,3,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 200 uM after 24 hrs by LDH release assay,Other,17875991.0,
624,433944,3,4,,103348651,6197,Unspecified,,,,,Cytotoxicity against human A375 cells assessed as inhibition of protein synthesis at 10 ug/mL,Other,19615898.0,
625,434955,1,2,,56463698,6197,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
626,434959,1,1,,85788478,6197,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
627,434962,1,2,,56463698,6197,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
628,434973,1,3,,56463698,6197,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
629,434989,1,1,,56463698,6197,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
630,435003,1,3,,56463698,6197,Active,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
631,435005,1,1,,56463698,6197,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
632,435006,1,2,,56463698,6197,Active,219518789.0,114548.0,,,Single concentration confirmation of uHTS for the identification of inhibitors of NALP3 in yeast using a luminescent assay,Screening,,
633,435020,1,2,,56463698,6197,Active,,,,,Single concentration confirmation of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
634,435022,2,2,,56463698,6197,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
635,435030,1,2,,56463698,6197,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
636,435030,1,2,,56463698,6197,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
637,449703,5,2,,103348651,6197,Active,,,0.1135,EC50,NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
638,449704,5,2,,103348651,6197,Active,,,0.1817,EC50,NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
639,449705,5,2,,103348651,6197,Unspecified,,,100.0,CC50,NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7),Confirmatory,18579783.0,
640,449706,5,2,,103348651,6197,Unspecified,,,,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.",Other,18579783.0,
641,449728,1,2,,56463698,6197,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
642,449762,1,2,,56463698,6197,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
643,449763,1,3,,56463698,6197,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
644,463079,1,2,,56463698,6197,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
645,463082,1,1,,56463698,6197,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
646,463104,1,2,,56463698,6197,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
647,463141,1,2,,56463698,6197,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
648,463190,1,2,,56463698,6197,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
649,463195,1,2,,56463698,6197,Active,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
650,463210,1,2,,56463698,6197,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
651,463212,1,1,,56463698,6197,Active,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
652,463215,1,2,,56463698,6197,Active,285809906.0,856395.0,,,Single concentration confirmation of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
653,463218,1,2,,56463698,6197,Active,285814664.0,855751.0,,,Single concentration confirmation of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
654,463254,1,1,,56463698,6197,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
655,471617,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 20 ug/disk after 72 hrs at 25 degreeC by disc diffusion method,Other,19711989.0,
656,471618,4,4,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 20 ug/disk after 72 hrs at 37 degreeC by disc diffusion method,Other,19711989.0,
657,471619,4,4,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 10 ug/disk after 72 hrs at 37 degreeC by disc diffusion method,Other,19711989.0,
658,471620,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 10 ug/disk after 72 hrs at 24 degreeC by disc diffusion method,Other,19711989.0,
659,471621,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 5 ug/disk after 72 hrs at 24 degreeC by disc diffusion method,Other,19711989.0,
660,471622,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 5 ug/disk after 72 hrs at 37 degreeC by disc diffusion method,Other,19711989.0,
661,471623,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 2.5 ug/disk after 72 hrs at 24 degreeC by disc diffusion method,Other,19711989.0,
662,471624,3,7,,103348651,6197,Unspecified,,,,,Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 2.5 ug/disk after 72 hrs at 37 degreeC by disc diffusion method,Other,19711989.0,
663,478071,5,3,,103348651,6197,Active,,,0.26,IC50,Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay,Confirmatory,20356064.0,
664,478108,6,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Phoma CCF3818 assessed as inhibition of hyphae elongation after 24 hrs,Other,20369841.0,
665,485270,1,1,,56463698,6197,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
666,485272,1,1,,56463698,6197,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
667,485273,2,1,,56463698,6197,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
668,485275,1,3,,56463698,6197,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
669,485290,1,1,,17389082,6197,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
670,485290,1,1,,17389083,6197,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
671,485290,1,1,,50104677,6197,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
672,485290,1,1,,56463698,6197,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
673,485294,1,1,,56463698,6197,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
674,485297,1,1,,56463698,6197,Inactive,4759012.0,9367.0,0.3162,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
675,485298,1,1,,56463698,6197,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
676,485313,1,2,,56463698,6197,Inactive,255652944.0,4864.0,0.4467,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
677,485317,1,2,,56463698,6197,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
678,485341,1,1,,56463698,6197,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
679,485344,1,1,,56463698,6197,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
680,485346,1,1,,56463698,6197,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
681,485346,1,1,,56463698,6197,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
682,485347,1,2,,56463698,6197,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
683,485349,1,1,,56463698,6197,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
684,485350,1,2,,92124468,6197,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
685,485350,1,2,,92125866,6197,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
686,485353,2,1,,56463698,6197,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
687,485358,1,1,,56463698,6197,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
688,485360,1,1,,56463698,6197,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
689,485364,1,1,,56463698,6197,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
690,485367,1,2,,56463698,6197,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
691,488784,1,2,,56463698,6197,Active,219518789.0,114548.0,,,Single concentration confirmation of inhibitors of NALP3 in yeast using a Caspase-1-ASC counter screen,Screening,,
692,488792,1,3,,96099772,6197,Inactive,85666113.0,850333.0,,EC50_MICROM,"Confirmatory Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically AGP1",Confirmatory,,
693,488794,1,2,,56463698,6197,Active,219518789.0,114548.0,,,Single concentration confirmation of uHTS for the identification of inhibitors of NALP3 in yeast using a luminescent assay - retest,Screening,,
694,488795,1,3,,96099772,6197,Inactive,486173.0,,,EC50_MICROM,"Confirmatory Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically LAP4",Confirmatory,,
695,488801,1,3,,96099772,6197,Inactive,1302091.0,,,EC50_MICROM,"Confirmatory Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically MEP2",Confirmatory,,
696,488808,1,4,,96099772,6197,Active,536029.0,,0.87,EC50_MICROM,"Confirmatory Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically RPL19A",Confirmatory,,
697,488827,1,3,,96099772,6197,Inactive,171229.0,,,EC50_MICROM,"Confirmatory Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically CIT2",Confirmatory,,
698,488829,1,3,,96099772,6197,Inactive,,,,,"Phenotypic Counterscreen Primary Screen Hits KU SAR Dose Response Multiplex in TOR pathway GFP-fusion proteins for Saccharomyes cerevisiae, specifically s288c",Other,,
699,488837,1,1,,56463698,6197,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
700,488839,1,1,,56463698,6197,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
701,488839,1,1,,56463698,6197,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
702,488847,1,3,,56463698,6197,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
703,488862,1,1,,56463698,6197,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
704,488890,1,2,,56463698,6197,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
705,488895,1,2,,56463698,6197,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
706,488896,1,1,,56463698,6197,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
707,488899,1,1,,56463698,6197,Active,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
708,488965,1,2,,56463698,6197,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
709,488966,1,1,,56463698,6197,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
710,489026,1,2,,56463698,6197,Inactive,,,80.0,IC50_Mean,Dose response cytotoxicity of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
711,489028,1,2,,56463698,6197,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
712,489028,1,2,,56463698,6197,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
713,489030,2,1,,56463698,6197,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
714,489031,2,1,,56463698,6197,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
715,489033,1,2,,56463698,6197,Active,,,0.93,IC50_Mean,Dose Response selectivity of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a 697B cell line using a luminescence assay,Confirmatory,,
716,489035,1,1,,56463698,6197,Inactive,,,80.0,IC50_Mean,Dose response confirmation of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a Jurkat cell line using a luminescence assay,Confirmatory,,
717,489041,1,2,,56463698,6197,Active,,,0.54,IC50_Mean,Dose response counterscreen of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
718,492947,1,1,,56463698,6197,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
719,492953,1,1,,56463698,6197,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
720,492956,1,1,,56463698,6197,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
721,492967,1,2,,92125866,6197,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
722,492967,1,2,,99301138,6197,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
723,492972,1,1,,56463698,6197,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
724,493005,1,1,,56463698,6197,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
725,493008,1,1,,56463698,6197,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
726,493008,1,1,,56463698,6197,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
727,493008,1,1,,56463698,6197,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
728,493008,1,1,,56463698,6197,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
729,493011,1,1,,56463698,6197,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
730,493012,1,1,,56463698,6197,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
731,493014,1,1,,56463698,6197,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
732,493033,1,2,,92124468,6197,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
733,493033,1,2,,92125866,6197,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
734,493036,1,2,,56463698,6197,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
735,493056,1,1,,56463698,6197,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
736,493084,1,1,,56463698,6197,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
737,493087,1,1,,56463698,6197,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
738,493091,1,1,,56463698,6197,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
739,493098,1,1,,56463698,6197,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
740,493131,1,1,,56463698,6197,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
741,493140,1,1,,103914364,6197,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
742,493160,1,1,,56463698,6197,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
743,493162,1,2,,99301138,6197,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
744,493187,1,2,,56463698,6197,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
745,493244,1,1,,56463698,6197,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
746,493244,1,1,,56463698,6197,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
747,493244,1,1,,56463698,6197,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
748,493244,1,1,,56463698,6197,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
749,497859,3,4,,103348651,6197,Inactive,,,,,Inhibition of cellular necroptosis in TNFalpha treated FADD and RIP1 deficient human Jurkat cells at 30 uM,Other,18408713.0,
750,500485,2,4,,103348651,6197,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae W303-1A in glucose agar media at 0.5 ug after 24 hrs by disk diffusion method,Other,18516048.0,
751,500913,2,3,,103348651,6197,Active,,,,,Inhibition of AML1-ETO protein translation in heterozygous transgenic zebrafish assessed as suppression of phenotype appearance,Other,19172146.0,
752,500918,3,3,,103348651,6197,Active,,,,,Inhibition of Hsp70 expression in heterozygous transgenic zebrafish embryo at 0.15 uM by Western blot analysis,Other,19172146.0,
753,501214,3,4,,103348651,6197,Active,,,0.5325,IC50,Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy,Confirmatory,20118940.0,
754,501215,2,4,,103348651,6197,Active,,,2.8801,IC50,Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting,Confirmatory,20118940.0,
755,501216,2,3,,103348651,6197,Inactive,,,,,Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 100 uM after 30 mins by spectrophotometry,Other,20118940.0,
756,501217,2,3,,103348651,6197,Inactive,,,,,Effect on polyribosome profiling in human HEK293T cells assessed as accumulation of 80S ribosomes at 100 uM after 30 mins by spectrophotometry,Other,20118940.0,
757,501218,2,3,,103348651,6197,Active,,,,,Effect on polyribosome profiling assessed as accumulation of 80S ribosomes after 15 mins by scintillation spectroscopy,Other,20118940.0,
758,501220,3,3,,103348651,6197,Inactive,,,,,Inhibition of translational activity in rabbit reticulocyte assessed as occurrence of ribosomal arrest at start codon at 10 mM by toeprinting assay,Other,20118940.0,
759,501225,3,6,,103348651,6197,Inactive,,,,,Inhibition of eEF1A-mediated tRNA binding to ternary complex at 200 uM after 10 mins by filtration binding assay,Other,20118940.0,
760,501227,3,6,,103348651,6197,Active,,,,,Inhibition of eEF2-mediated tRNA translocation assessed as inhibition of phenylalanyl puromycin formation,Other,20118940.0,
761,501228,3,6,,103348651,6197,Active,,,,,Inhibition of eEF2-mediated tRNA translocation assessed as decrease in tripeptide (Met-Phe-Phe) formation by TLC,Other,20118940.0,
762,501229,3,6,,103348651,6197,Active,,,,,Inhibition of eEF2-mediated tRNA translocation assessed as induction of dipeptide accumulation by TLC,Other,20118940.0,
763,501230,4,2,,103348651,6197,Active,,,20.54,IC50,Antimicrobial activity against Saccharomyces cerevisiae J407alpha expressing ribosomal protein cyh2 and harboring mutation in rpl28,Confirmatory,20118940.0,
764,501231,6,1,,103348651,6197,Unspecified,,,,Kd,Binding affinity to 60S ribosome E-site by footprinting assay,Confirmatory,20118940.0,
765,501241,4,2,,103348651,6197,Active,,,0.08800000000000001,IC50,Antimicrobial activity against Saccharomyces cerevisiae J47alpha,Confirmatory,20118940.0,
766,501242,4,2,,103348651,6197,Active,,,0.032,IC50,Antimicrobial activity against Saccharomyces cerevisiae JB503,Confirmatory,20118940.0,
767,501243,4,2,,103348651,6197,Active,,,7.42,IC50,Antimicrobial activity against Saccharomyces cerevisiae BY686 expressing ribosomal protein cyh2 and harboring mutation in rpl28,Confirmatory,20118940.0,
768,501244,4,2,,103348651,6197,Active,,,0.675,IC50,Antimicrobial activity against Saccharomyces cerevisiae BY108,Confirmatory,20118940.0,
769,501245,4,2,,103348651,6197,Unspecified,,,52.07,IC50,Antimicrobial activity against Saccharomyces cerevisiae BY724 expressing ribosomal protein cyh2 and harboring mutation in rpl28,Confirmatory,20118940.0,
770,501246,4,2,,103348651,6197,Active,,,0.2273,IC50,Antimicrobial activity against Saccharomyces cerevisiae JB281,Confirmatory,20118940.0,
771,501247,4,2,,103348651,6197,Active,,,17.34,IC50,Antimicrobial activity against Saccharomyces cerevisiae BY740 expressing ribosomal protein cyh2 and harboring mutation in rpl28,Confirmatory,20118940.0,
772,501248,2,3,,103348651,6197,Unspecified,,,,,"Fold resistance, ratio of IC50 Saccharomyces cerevisiae J407alpha expressing ribosomal protein cyh2 and harboring mutation in rpl28 to IC50 for Saccharomyces cerevisiae J47alpha",Other,20118940.0,
773,501249,2,3,,103348651,6197,Unspecified,,,,,"Fold resistance, ratio of IC50 for Saccharomyces cerevisiae BY686 expressing ribosomal protein cyh2 and harboring mutation in rpl28 to IC50 Saccharomyces cerevisiae JB503",Other,20118940.0,
774,501250,2,3,,103348651,6197,Unspecified,,,,,"Fold resistance, ratio of IC50 for Saccharomyces cerevisiae BY724 expressing ribosomal protein cyh2 and harboring mutation in rpl28 to IC50 for Saccharomyces cerevisiae BY108",Other,20118940.0,
775,501251,2,3,,103348651,6197,Unspecified,,,,,"Fold resistance, ratio of IC50 for Saccharomyces cerevisiae BY740 expressing ribosomal protein cyh2 and harboring mutation in rpl28 to IC50 for Saccharomyces cerevisiae BY281",Other,20118940.0,
776,501252,2,3,,103348651,6197,Active,,,,,Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry,Other,20118940.0,
777,501255,3,3,,103348651,6197,Inactive,,,,,Inhibition of [32P]deacetylated phe-tRNA binding to 60S ribosome E-site by footprinting assay,Other,20118940.0,
778,504326,1,2,,56463698,6197,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
779,504326,1,2,,56463698,6197,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
780,504327,1,1,,56463698,6197,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
781,504329,1,1,,56463698,6197,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
782,504332,1,1,,56463698,6197,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
783,504333,1,1,,56463698,6197,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
784,504339,1,1,,56463698,6197,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
785,504357,1,1,,56463698,6197,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
786,504357,1,1,,56463698,6197,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
787,504406,1,1,,56463698,6197,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
788,504411,1,1,,56463698,6197,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
789,504414,1,1,,56463698,6197,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
790,504414,1,1,,56463698,6197,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
791,504423,1,1,,56463698,6197,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
792,504444,1,1,,56463698,6197,Active,224028257.0,4780.0,0.5805,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
793,504454,1,3,,56463698,6197,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
794,504456,1,1,,96099772,6197,Inactive,,,,,Yeast TORC1 Bypass Cell Growth Assay,Other,,
795,504462,1,1,,56463698,6197,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
796,504466,1,1,,56463698,6197,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
797,504467,1,1,,56463698,6197,Active,116283940.0,79915.0,0.2908,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
798,504490,1,2,,56463698,6197,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
799,504523,1,1,,56463698,6197,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
800,504523,1,1,,56463698,6197,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
801,504558,1,1,,56463698,6197,Active,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
802,504577,2,2,,56463698,6197,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
803,504582,2,1,,56463698,6197,Active,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
804,504601,1,1,,56463698,6197,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format - Set 2,Screening,,
805,504601,1,1,,56463698,6197,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format - Set 2,Screening,,
806,504607,1,1,,56463698,6197,Active,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
807,504621,1,1,,56463698,6197,Active,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
808,504634,1,1,,56463698,6197,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
809,504648,1,1,,56463698,6197,Inconclusive,,,0.4611,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
810,504651,1,1,,56463698,6197,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
811,504660,1,1,,56463698,6197,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
812,504668,1,1,,56463698,6197,Active,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
813,504668,1,1,,56463698,6197,Active,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
814,504690,1,3,,56463698,6197,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
815,504692,2,2,,56463698,6197,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
816,504700,1,1,,56463698,6197,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
817,504700,1,1,,56463698,6197,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
818,504706,1,1,,56463698,6197,Inconclusive,23491729.0,7157.0,28.1838,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
819,504707,1,1,,56463698,6197,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
820,504707,1,1,,56463698,6197,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
821,504720,1,1,,56463698,6197,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
822,504734,1,1,,56463698,6197,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
823,504766,2,1,,56463698,6197,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
824,504770,1,2,,92124468,6197,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
825,504775,1,1,,56463698,6197,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
826,504803,1,1,,56463698,6197,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
827,504810,1,2,,56463698,6197,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
828,504812,1,2,,56463698,6197,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
829,504832,1,1,,56463698,6197,Active,,,0.1042,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
830,504834,1,1,,56463698,6197,Active,,,0.1042,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
831,504842,1,1,,56463698,6197,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
832,504845,1,1,,56463698,6197,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
833,504847,1,1,,56463698,6197,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
834,504848,1,1,,56463698,6197,Active,,,0.7943,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
835,504850,1,1,,56463698,6197,Active,,,0.8913,Potency,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
836,504884,1,2,,56463698,6197,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
837,504891,1,1,,56463698,6197,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
838,504894,1,1,,56463698,6197,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
839,504937,1,2,,56463698,6197,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
840,507145,3,4,,103348651,6197,Active,,,,,Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis,Other,18066055.0,
841,507146,3,4,,103348651,6197,Active,,,,,Inhibition of mitosis in human HeLa cells by imaging analysis,Other,18066055.0,
842,510586,5,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution assay,Other,20605657.0,
843,510587,2,3,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by agar diffusion assay,Other,20605657.0,
844,510588,5,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Streptococcus pyogenes ATCC 19615 after 24 hrs by microdilution assay,Other,20605657.0,
845,510589,2,3,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Streptococcus pyogenes ATCC 19615 after 24 hrs by agar diffusion assay,Other,20605657.0,
846,510590,5,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas phaseolicola GSPB 2828 after 24 hrs by microdilution assay,Other,20605657.0,
847,510591,2,3,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas phaseolicola GSPB 2828 after 24 hrs by agar diffusion assay,Other,20605657.0,
848,510592,5,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas fluorescens S 97 after 24 hrs by microdilution assay,Other,20605657.0,
849,510593,2,3,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas fluorescens S 97 after 24 hrs by agar diffusion assay,Other,20605657.0,
850,510594,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum after 48 hrs by microdilution assay,Other,20605657.0,
851,510595,1,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum after 48 hrs by agar diffusion assay,Other,20605657.0,
852,510596,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus after 48 hrs by microdilution assay,Other,20605657.0,
853,510597,1,3,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus after 48 hrs by agar diffusion assay,Other,20605657.0,
854,510926,2,4,,103348651,6197,Active,,,0.32,IC50,Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
855,510927,2,4,,103348651,6197,Active,,,0.287,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
856,510928,2,4,,103348651,6197,Active,,,0.31,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
857,510929,2,4,,103348651,6197,Active,,,0.301,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
858,510939,6,1,,103348651,6197,Active,,,0.2,IC50,Antimalarial activity against Plasmodium falciparum assessed as [35S]Met/Cys incorporation by SYBR green based fluorescence assay,Confirmatory,20813948.0,
859,510944,3,4,,103348651,6197,Active,,,,,Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone1 within 1 hrs by [35S]Met/Cys incorporation assay,Other,20813948.0,
860,510945,3,4,,103348651,6197,Active,,,,,Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone3 within 1 hrs by [35S]Met/Cys incorporation assay,Other,20813948.0,
861,519674,5,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against wild type Saccharomyces cerevisiae BY4741 by broth microdilution method,Other,18212113.0,
862,519675,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in SNF1 gene by broth microdilution method,Other,18212113.0,
863,519676,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in IFA38 gene by broth microdilution method,Other,18212113.0,
864,519677,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in OP11 gene by broth microdilution method,Other,18212113.0,
865,519678,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in RTG2 gene by broth microdilution method,Other,18212113.0,
866,519679,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in APL2 gene by broth microdilution method,Other,18212113.0,
867,519680,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in RAD18 gene by broth microdilution method,Other,18212113.0,
868,519681,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in YGL235W gene by broth microdilution method,Other,18212113.0,
869,519682,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in YOR345C gene by broth microdilution method,Other,18212113.0,
870,519683,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in YLR456W gene by broth microdilution method,Other,18212113.0,
871,519684,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in YGL072C gene by broth microdilution method,Other,18212113.0,
872,519685,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in CYS3 gene by broth microdilution method,Other,18212113.0,
873,519686,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in MEF2 gene by broth microdilution method,Other,18212113.0,
874,519687,4,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae containing disruption in YKL037W gene by broth microdilution method,Other,18212113.0,
875,521208,4,2,,103348651,6197,Active,,,0.142,EC50,Antiproliferative activity against mouse neural precursor cells by MTT assay,Confirmatory,17417631.0,
876,521209,4,3,,103348651,6197,Active,,,0.071,EC50,Antiproliferative activity against mouse astrocyte cells by MTT assay,Confirmatory,17417631.0,
877,521210,4,1,,103348651,6197,Unspecified,,,,,Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay,Other,17417631.0,
878,521214,4,2,,103348651,6197,Active,,,0.042,EC50,Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay,Confirmatory,17417631.0,
879,521215,4,2,,103348651,6197,Active,,,0.054000000000000006,EC50,Antiproliferative activity against mouse neural precursor cells by colony formation assay,Confirmatory,17417631.0,
880,521220,3,3,,103348651,6197,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
881,521221,2,4,,103348651,6197,Active,,,,,Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM,Other,17417631.0,
882,523667,3,3,,103348651,6197,Active,,,,,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase UL54 mRNA expression after 16 hrs by RT-PCR analysis,Other,20194695.0,
883,523668,3,3,,103348651,6197,Active,,,,,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase UL84 mRNA expression after 16 hrs by RT-PCR analysis,Other,20194695.0,
884,523669,3,3,,103348651,6197,Active,,,,,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase P72 protein expression after 24 hrs by Western blot analysis,Other,20194695.0,
885,523670,3,3,,103348651,6197,Active,,,,,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase P86 protein expression after 24 hrs by Western blot analysis,Other,20194695.0,
886,534106,5,2,,103348651,6197,Unspecified,,,,,Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method,Other,18725450.0,
887,534107,5,2,,103348651,6197,Unspecified,,,,,Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method,Other,18725450.0,
888,534108,5,2,,103348651,6197,Unspecified,,,,,Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method,Other,18725450.0,
889,534109,1,3,,103348651,6197,Unspecified,,,,,Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm0527,Other,18725450.0,
890,534110,5,2,,103348651,6197,Unspecified,,,,,Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method,Other,18725450.0,
891,534111,5,2,,103348651,6197,Unspecified,,,,,Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method,Other,18725450.0,
892,534112,1,3,,103348651,6197,Unspecified,,,,,Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm1980,Other,18725450.0,
893,537733,2,3,,103348651,6197,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
894,537734,5,2,,103348651,6197,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
895,537735,2,3,,103348651,6197,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
896,537736,5,2,,103348651,6197,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
897,540253,1,1,,56463698,6197,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
898,540253,1,1,,56463698,6197,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
899,540253,1,1,,56463698,6197,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
900,540263,1,1,,56463698,6197,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
901,540263,1,1,,56463698,6197,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
902,540267,1,1,,56463698,6197,Active,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
903,540268,1,1,,56463698,6197,Active,124809506.0,811999.0,0.195,AC50_uM,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
904,540270,1,1,,56463698,6197,Active,154146191.0,3320.0,0.195,AC50_uM,HsHsp90 Counterscreen Measured in Microorganism System Using Plate Reader - 2121-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
905,540275,1,1,,56463698,6197,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
906,540277,1,1,,56463698,6197,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
907,540295,1,1,,56463698,6197,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
908,540299,1,2,,92124468,6197,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
909,540299,1,2,,92125866,6197,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
910,540303,1,1,,56463698,6197,Active,6679377.0,18792.0,0.5012,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
911,540303,1,1,,56463698,6197,Active,7242179.0,18793.0,0.5012,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
912,540303,1,1,,56463698,6197,Active,257471003.0,18815.0,0.5012,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
913,540308,1,1,,56463698,6197,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
914,540317,1,1,,56463698,6197,Inactive,187960037.0,10951.0,79.4328,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
915,540336,1,1,,56463698,6197,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
916,540336,1,1,,56463698,6197,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
917,540364,1,2,,56463698,6197,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
918,547621,4,3,,103348651,6197,Unspecified,,,50.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
919,547622,4,2,,103348651,6197,Active,,,0.4,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
920,547804,1,3,,103348651,6197,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
921,552436,3,4,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger ATCC 16404 after 24 to 48 hrs by paper disk diffusion assay,Other,21215645.0,
922,552437,3,4,,103348651,6197,Unspecified,,,,,Antifungal activity against Penicillium aurantiogriseum ATCC 16025 after 24 to 48 hrs by paper disk diffusion assay,Other,21215645.0,
923,554735,2,9,,103348651,6197,Active,121732831.0,,,,Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 0.37 nM,Other,19015352.0,
924,588334,1,1,,56463698,6197,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
925,588335,1,1,,56463698,6197,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
926,588342,1,1,,56463698,6197,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
927,588352,1,2,,56463698,6197,Active,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
928,588354,1,1,,56463698,6197,Active,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
929,588358,1,2,,56463698,6197,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
930,588379,1,2,,124883128,6197,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
931,588382,1,2,,56463698,6197,Inactive,,,,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox,Confirmatory,,
932,588397,1,1,,56463698,6197,Active,,,0.1831,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation.,Confirmatory,,
933,588405,1,1,,56463698,6197,Active,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
934,588413,1,2,,56463698,6197,Active,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
935,588436,1,1,,56463698,6197,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
936,588453,1,1,,56463698,6197,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
937,588456,1,1,,56463698,6197,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
938,588458,1,1,,56463698,6197,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
939,588473,1,1,,56463698,6197,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
940,588473,1,1,,56463698,6197,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
941,588475,1,2,,56463698,6197,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
942,588475,1,2,,56463698,6197,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
943,588489,1,1,,56463698,6197,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
944,588492,1,1,,56463698,6197,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
945,588493,1,2,,56463698,6197,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
946,588497,1,2,,56463698,6197,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
947,588497,1,2,,56463698,6197,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
948,588497,1,2,,56463698,6197,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
949,588499,1,3,,56463698,6197,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
950,588499,1,3,,56463698,6197,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
951,588499,1,3,,56463698,6197,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
952,588501,1,2,,56463698,6197,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
953,588501,1,2,,56463698,6197,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
954,588501,1,2,,56463698,6197,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
955,588513,1,1,,17389082,6197,Inactive,348019627.0,2099.0,17.7828,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
956,588513,1,1,,17389083,6197,Inactive,348019627.0,2099.0,1.7783,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
957,588513,1,1,,26752000,6197,Inconclusive,348019627.0,2099.0,1.5849,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
958,588514,1,1,,17389082,6197,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
959,588514,1,1,,17389083,6197,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
960,588514,1,1,,26752000,6197,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
961,588515,1,1,,17389082,6197,Inconclusive,124375976.0,367.0,0.5012,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
962,588515,1,1,,17389083,6197,Inconclusive,124375976.0,367.0,1.4125,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
963,588515,1,1,,26752000,6197,Inconclusive,124375976.0,367.0,3.1623,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
964,588516,1,1,,17389082,6197,Inconclusive,124375976.0,367.0,0.1122,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
965,588516,1,1,,17389083,6197,Inconclusive,124375976.0,367.0,0.3162,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
966,588516,1,1,,26752000,6197,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
967,588519,1,2,,92124468,6197,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
968,588519,1,2,,92125866,6197,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
969,588526,1,1,,17389082,6197,Inconclusive,325495553.0,9971.0,50.1187,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
970,588526,1,1,,17389083,6197,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
971,588526,1,1,,26752000,6197,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
972,588527,1,1,,17389082,6197,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
973,588527,1,1,,17389083,6197,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
974,588527,1,1,,26752000,6197,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
975,588532,1,1,,17389082,6197,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
976,588532,1,1,,17389083,6197,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
977,588532,1,1,,26752000,6197,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
978,588533,1,1,,17389082,6197,Active,311348376.0,2908.0,3.1623,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
979,588533,1,1,,17389083,6197,Inconclusive,311348376.0,2908.0,1.4125,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
980,588533,1,1,,26752000,6197,Inconclusive,311348376.0,2908.0,2.8184,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
981,588534,1,1,,17389082,6197,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
982,588534,1,1,,17389083,6197,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
983,588534,1,1,,26752000,6197,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
984,588535,1,1,,17389082,6197,Active,216409690.0,5467.0,0.3162,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
985,588535,1,1,,17389083,6197,Active,216409690.0,5467.0,0.1995,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
986,588535,1,1,,26752000,6197,Inconclusive,216409690.0,5467.0,0.0562,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
987,588536,1,1,,17389082,6197,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
988,588536,1,1,,17389083,6197,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
989,588536,1,1,,26752000,6197,Inconclusive,216409692.0,5468.0,28.1838,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
990,588537,1,1,,17389082,6197,Inconclusive,216409692.0,5468.0,44.6684,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
991,588537,1,1,,17389083,6197,Inconclusive,216409692.0,5468.0,63.0957,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
992,588537,1,1,,26752000,6197,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
993,588541,1,1,,17389082,6197,Inconclusive,216409708.0,7421.0,14.1254,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
994,588541,1,1,,17389083,6197,Inconclusive,216409708.0,7421.0,10.0,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
995,588541,1,1,,26752000,6197,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
996,588543,1,1,,17389082,6197,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
997,588543,1,1,,17389083,6197,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
998,588543,1,1,,26752000,6197,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
999,588544,1,1,,17389082,6197,Inconclusive,325495497.0,6256.0,0.5012,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1000,588544,1,1,,17389083,6197,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1001,588544,1,1,,26752000,6197,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1002,588545,1,1,,17389082,6197,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1003,588545,1,1,,17389083,6197,Inconclusive,189491771.0,7068.0,0.0447,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1004,588545,1,1,,26752000,6197,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1005,588546,1,1,,17389082,6197,Inconclusive,325495497.0,6256.0,0.3162,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1006,588546,1,1,,17389083,6197,Inconclusive,325495497.0,6256.0,1.2589,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1007,588546,1,1,,26752000,6197,Inconclusive,325495497.0,6256.0,3.5481,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1008,588547,1,1,,17389082,6197,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1009,588547,1,1,,17389083,6197,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1010,588547,1,1,,26752000,6197,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1011,588549,1,1,,56463698,6197,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1012,588579,1,1,,56463698,6197,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1013,588579,1,1,,124883128,6197,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1014,588590,1,1,,56463698,6197,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1015,588591,1,1,,56463698,6197,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1016,588621,1,1,,56463698,6197,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1017,588664,1,2,,56463698,6197,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1018,588664,1,2,,56463698,6197,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1019,588674,1,2,,56463698,6197,Active,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1020,588689,1,1,,56463698,6197,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1021,588692,2,1,,56463698,6197,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1022,588726,1,2,,56463698,6197,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1023,588727,1,1,,56463698,6197,Inconclusive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1024,588795,1,1,,56463698,6197,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1025,588812,1,1,,17389082,6197,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1026,588812,1,1,,17389083,6197,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1027,588812,1,1,1.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1028,588812,1,1,1.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1029,588812,1,1,2.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1030,588812,1,1,2.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1031,588812,1,1,3.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1032,588812,1,1,3.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1033,588812,1,1,4.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1034,588812,1,1,4.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1035,588812,1,1,5.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1036,588812,1,1,5.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1037,588812,1,1,6.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1038,588812,1,1,6.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1039,588812,1,1,7.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1040,588812,1,1,7.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1041,588812,1,1,8.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1042,588812,1,1,8.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1043,588812,1,1,9.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1044,588812,1,1,9.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1045,588812,1,1,10.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1046,588812,1,1,10.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1047,588812,1,1,11.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1048,588812,1,1,11.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1049,588812,1,1,12.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1050,588812,1,1,12.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1051,588812,1,1,13.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1052,588812,1,1,13.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1053,588812,1,1,14.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1054,588812,1,1,14.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1055,588812,1,1,15.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1056,588812,1,1,15.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1057,588812,1,1,16.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1058,588812,1,1,16.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1059,588812,1,1,17.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1060,588812,1,1,17.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1061,588812,1,1,18.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1062,588812,1,1,18.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1063,588812,1,1,19.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1064,588812,1,1,19.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1065,588812,1,1,20.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1066,588812,1,1,20.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1067,588812,1,1,21.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1068,588812,1,1,21.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1069,588812,1,1,22.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1070,588812,1,1,22.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1071,588812,1,1,23.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1072,588812,1,1,23.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1073,588812,1,1,24.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1074,588812,1,1,24.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1075,588812,1,1,25.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1076,588812,1,1,25.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1077,588812,1,1,26.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1078,588812,1,1,26.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1079,588812,1,1,27.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1080,588812,1,1,27.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1081,588812,1,1,28.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1082,588812,1,1,28.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1083,588812,1,1,29.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1084,588812,1,1,29.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1085,588812,1,1,30.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1086,588812,1,1,30.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1087,588812,1,1,31.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1088,588812,1,1,31.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1089,588812,1,1,32.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1090,588812,1,1,32.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1091,588812,1,1,33.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1092,588812,1,1,33.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1093,588812,1,1,34.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1094,588812,1,1,34.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1095,588812,1,1,35.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1096,588812,1,1,35.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1097,588812,1,1,36.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1098,588812,1,1,36.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1099,588812,1,1,37.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1100,588812,1,1,37.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1101,588812,1,1,38.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1102,588812,1,1,38.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1103,588812,1,1,39.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1104,588812,1,1,39.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1105,588812,1,1,40.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1106,588812,1,1,40.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1107,588812,1,1,41.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1108,588812,1,1,41.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1109,588812,1,1,42.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1110,588812,1,1,42.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1111,588812,1,1,43.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1112,588812,1,1,43.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1113,588812,1,1,44.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1114,588812,1,1,44.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1115,588812,1,1,45.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1116,588812,1,1,45.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1117,588812,1,1,46.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1118,588812,1,1,46.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1119,588812,1,1,47.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1120,588812,1,1,47.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1121,588812,1,1,48.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1122,588812,1,1,48.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1123,588812,1,1,49.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1124,588812,1,1,49.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1125,588812,1,1,50.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1126,588812,1,1,50.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1127,588812,1,1,51.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1128,588812,1,1,51.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1129,588812,1,1,52.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1130,588812,1,1,52.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1131,588812,1,1,53.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1132,588812,1,1,53.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1133,588812,1,1,54.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1134,588812,1,1,54.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1135,588812,1,1,55.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1136,588812,1,1,55.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1137,588812,1,1,56.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1138,588812,1,1,56.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1139,588812,1,1,57.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1140,588812,1,1,57.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1141,588812,1,1,58.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1142,588812,1,1,58.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1143,588812,1,1,59.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1144,588812,1,1,59.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1145,588812,1,1,60.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1146,588812,1,1,60.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1147,588812,1,1,61.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1148,588812,1,1,61.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1149,588812,1,1,62.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1150,588812,1,1,62.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1151,588812,1,1,63.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1152,588812,1,1,63.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1153,588812,1,1,64.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1154,588812,1,1,64.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1155,588812,1,1,65.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1156,588812,1,1,65.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1157,588812,1,1,66.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1158,588812,1,1,66.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1159,588812,1,1,67.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1160,588812,1,1,67.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1161,588812,1,1,68.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1162,588812,1,1,68.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1163,588812,1,1,69.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1164,588812,1,1,69.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1165,588812,1,1,70.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1166,588812,1,1,70.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1167,588812,1,1,71.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1168,588812,1,1,71.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1169,588812,1,1,72.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1170,588812,1,1,72.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1171,588812,1,1,73.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1172,588812,1,1,73.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1173,588812,1,1,74.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1174,588812,1,1,74.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1175,588812,1,1,75.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1176,588812,1,1,75.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1177,588812,1,1,76.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1178,588812,1,1,76.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1179,588812,1,1,77.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1180,588812,1,1,77.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1181,588812,1,1,78.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1182,588812,1,1,78.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1183,588812,1,1,79.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1184,588812,1,1,79.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1185,588812,1,1,80.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1186,588812,1,1,80.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1187,588812,1,1,81.0,17389082,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1188,588812,1,1,81.0,17389083,6197,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1189,588813,1,1,,17389082,6197,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1190,588813,1,1,,17389083,6197,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1191,588813,1,1,1.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1192,588813,1,1,1.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1193,588813,1,1,2.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1194,588813,1,1,2.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1195,588813,1,1,3.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1196,588813,1,1,3.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1197,588813,1,1,4.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1198,588813,1,1,4.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1199,588813,1,1,5.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1200,588813,1,1,5.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1201,588813,1,1,6.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1202,588813,1,1,6.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1203,588813,1,1,7.0,17389082,6197,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1204,588813,1,1,7.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1205,588813,1,1,8.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1206,588813,1,1,8.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1207,588813,1,1,9.0,17389082,6197,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1208,588813,1,1,9.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1209,588813,1,1,10.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1210,588813,1,1,10.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1211,588813,1,1,11.0,17389082,6197,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1212,588813,1,1,11.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1213,588813,1,1,12.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1214,588813,1,1,12.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1215,588813,1,1,13.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1216,588813,1,1,13.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1217,588813,1,1,14.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1218,588813,1,1,14.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1219,588813,1,1,15.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1220,588813,1,1,15.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1221,588813,1,1,16.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1222,588813,1,1,16.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1223,588813,1,1,17.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1224,588813,1,1,17.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1225,588813,1,1,18.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1226,588813,1,1,18.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1227,588813,1,1,19.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1228,588813,1,1,19.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1229,588813,1,1,20.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1230,588813,1,1,20.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1231,588813,1,1,21.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1232,588813,1,1,21.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1233,588813,1,1,22.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1234,588813,1,1,22.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1235,588813,1,1,23.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1236,588813,1,1,23.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1237,588813,1,1,24.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1238,588813,1,1,24.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1239,588813,1,1,25.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1240,588813,1,1,25.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1241,588813,1,1,26.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1242,588813,1,1,26.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1243,588813,1,1,27.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1244,588813,1,1,27.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1245,588813,1,1,28.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1246,588813,1,1,28.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1247,588813,1,1,29.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1248,588813,1,1,29.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1249,588813,1,1,30.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1250,588813,1,1,30.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1251,588813,1,1,31.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1252,588813,1,1,31.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1253,588813,1,1,32.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1254,588813,1,1,32.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1255,588813,1,1,33.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1256,588813,1,1,33.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1257,588813,1,1,34.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1258,588813,1,1,34.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1259,588813,1,1,35.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1260,588813,1,1,35.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1261,588813,1,1,36.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1262,588813,1,1,36.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1263,588813,1,1,37.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1264,588813,1,1,37.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1265,588813,1,1,38.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1266,588813,1,1,38.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1267,588813,1,1,39.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1268,588813,1,1,39.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1269,588813,1,1,40.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1270,588813,1,1,40.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1271,588813,1,1,41.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1272,588813,1,1,41.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1273,588813,1,1,42.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1274,588813,1,1,42.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1275,588813,1,1,43.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1276,588813,1,1,43.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1277,588813,1,1,44.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1278,588813,1,1,44.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1279,588813,1,1,45.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1280,588813,1,1,45.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1281,588813,1,1,46.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1282,588813,1,1,46.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1283,588813,1,1,47.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1284,588813,1,1,47.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1285,588813,1,1,48.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1286,588813,1,1,48.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1287,588813,1,1,49.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1288,588813,1,1,49.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1289,588813,1,1,50.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1290,588813,1,1,50.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1291,588813,1,1,51.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1292,588813,1,1,51.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1293,588813,1,1,52.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1294,588813,1,1,52.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1295,588813,1,1,53.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1296,588813,1,1,53.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1297,588813,1,1,54.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1298,588813,1,1,54.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1299,588813,1,1,55.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1300,588813,1,1,55.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1301,588813,1,1,56.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1302,588813,1,1,56.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1303,588813,1,1,57.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1304,588813,1,1,57.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1305,588813,1,1,58.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1306,588813,1,1,58.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1307,588813,1,1,59.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1308,588813,1,1,59.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1309,588813,1,1,60.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1310,588813,1,1,60.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1311,588813,1,1,61.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1312,588813,1,1,61.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1313,588813,1,1,62.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1314,588813,1,1,62.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1315,588813,1,1,63.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1316,588813,1,1,63.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1317,588813,1,1,64.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1318,588813,1,1,64.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1319,588813,1,1,65.0,17389082,6197,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1320,588813,1,1,65.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1321,588813,1,1,66.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1322,588813,1,1,66.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1323,588813,1,1,67.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1324,588813,1,1,67.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1325,588813,1,1,68.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1326,588813,1,1,68.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1327,588813,1,1,69.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1328,588813,1,1,69.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1329,588813,1,1,70.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1330,588813,1,1,70.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1331,588813,1,1,71.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1332,588813,1,1,71.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1333,588813,1,1,72.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1334,588813,1,1,72.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1335,588813,1,1,73.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1336,588813,1,1,73.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1337,588813,1,1,74.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1338,588813,1,1,74.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1339,588813,1,1,75.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1340,588813,1,1,75.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1341,588813,1,1,76.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1342,588813,1,1,76.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1343,588813,1,1,77.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1344,588813,1,1,77.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1345,588813,1,1,78.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1346,588813,1,1,78.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1347,588813,1,1,79.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1348,588813,1,1,79.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1349,588813,1,1,80.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1350,588813,1,1,80.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1351,588813,1,1,81.0,17389082,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1352,588813,1,1,81.0,17389083,6197,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1353,588814,1,3,,56463698,6197,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1354,588819,1,4,,56463698,6197,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1355,588832,1,1,,56463698,6197,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1356,588834,2,1,,17389082,6197,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1357,588834,2,1,,17389083,6197,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1358,588850,1,1,,56463698,6197,Active,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1359,588852,1,3,,56463698,6197,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1360,588855,1,1,,56463698,6197,Active,18418623.0,4088.0,1.0,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1361,588856,1,1,,56463698,6197,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1362,589501,1,4,,103348651,6197,Unspecified,,,,,Inhibition of protein synthesis in human K562 cells assessed as [14C]L-leucine incorporation at 3.5 uM after 120 mins,Other,21376582.0,
1363,589502,1,4,,103348651,6197,Unspecified,,,,,Inhibition of transcription in human K562 cells at 3.5 uM after 120 mins,Other,21376582.0,
1364,592501,1,3,,103348651,6197,Unspecified,,,,,Antifungal activity against Microbotryum violaceum assessed as zone of inhibition measured as radius at 50 ug by agar diffusion assay,Other,21244021.0,
1365,592502,4,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Legionella pneumophila Corby by microtiter plate assay,Other,21244021.0,
1366,600831,4,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by serial dilution method,Other,21489661.0,
1367,600832,4,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Bacillus thuringiensis ATCC 6051 after 24 hrs by serial dilution method,Other,21489661.0,
1368,600833,4,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 14169 after 24 hrs by serial dilution method,Other,21489661.0,
1369,600834,4,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by serial dilution method,Other,21489661.0,
1370,600835,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum ATCC 16417 after 48 hrs by serial dilution method,Other,21489661.0,
1371,600836,4,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Botrytis fabae ATCC 14862 after 48 hrs by serial dilution method,Other,21489661.0,
1372,600837,1,4,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 at 1 mg/ml after 24 hrs by agar-diffusion method,Other,21489661.0,
1373,600838,1,4,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Bacillus thuringiensis ATCC 6051 at 1 mg/ml after 24 hrs by agar-diffusion method,Other,21489661.0,
1374,600839,1,4,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 14169 at 1 mg/ml after 24 hrs by agar-diffusion method,Other,21489661.0,
1375,600840,1,4,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 1 mg/ml after 24 hrs by agar-diffusion method,Other,21489661.0,
1376,600923,1,4,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum ATCC 16417 at 1 mg/ml after 48 hrs by agar-diffusion method,Other,21489661.0,
1377,600924,1,4,,103348651,6197,Unspecified,,,,,Antifungal activity against Botrytis fabae ATCC 14862 at 1 mg/ml after 48 hrs by agar-diffusion method,Other,21489661.0,
1378,602118,1,4,,103348651,6197,Active,,,,,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.",Other,22096101.0,
1379,602119,3,2,,103348651,6197,Active,,,0.0781,IC50,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration",Confirmatory,22096101.0,
1380,602123,1,1,,56463698,6197,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1381,602141,1,1,,56463698,6197,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1382,602156,1,1,,131332686,6197,Active,,,0.0781,IC50,Novartis GNF Liver Stage Dataset: Malariabox Annotation,Other,22096101.0,
1383,602162,1,1,,56463698,6197,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1384,602163,1,1,,56463698,6197,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1385,602179,1,2,,56463698,6197,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1386,602229,1,1,,56463698,6197,Active,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1387,602233,1,1,,56463698,6197,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1388,602244,1,2,,56463698,6197,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1389,602247,1,2,,56463698,6197,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1390,602248,1,2,,56463698,6197,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1391,602250,1,2,,56463698,6197,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1392,602252,1,1,,56463698,6197,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1393,602252,1,1,,56463698,6197,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1394,602261,1,1,,56463698,6197,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1395,602274,1,2,,56463698,6197,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1396,602281,1,1,,56463698,6197,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1397,602281,1,1,,56463698,6197,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1398,602310,1,2,,56463698,6197,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1399,602313,1,1,,56463698,6197,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1400,602314,1,2,,92124468,6197,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1401,602314,1,2,,92125866,6197,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1402,602329,1,1,,56463698,6197,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1403,602332,1,1,,56463698,6197,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1404,602332,1,1,,124883128,6197,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1405,602340,1,2,,56463698,6197,Active,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1406,602342,2,1,,56463698,6197,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1407,602346,1,1,,56463698,6197,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1408,602363,1,1,,56463698,6197,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1409,602393,1,1,,56463698,6197,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1410,602396,1,2,,56463698,6197,Active,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1411,602399,1,2,,56463698,6197,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1412,602405,1,1,,56463698,6197,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1413,602410,1,1,,56463698,6197,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1414,602417,1,1,,56463698,6197,Active,78486550.0,171071.0,,,Single concentration confirmation of uHTS hits for Peg3 Promoter Inhibitors via a luciferase reporter assay,Screening,,
1415,602429,1,1,,56463698,6197,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1416,602438,1,1,,56463698,6197,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1417,602440,1,1,,56463698,6197,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1418,602449,1,2,,56463698,6197,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1419,602472,1,1,,56463698,6197,Active,90421313.0,1080.0,,,Single concentration confirmation of uHTS hits for cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1420,602481,1,1,,56463698,6197,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1421,614240,1,4,,103348651,6197,Unspecified,,,,,Inhibition of total protein synthesis in Mucor mucedo IFO 7684 assessed as [U-14C]-leucine uptake into acid-insoluble fractions at 0.36 mM after 25 mins by liquid scintillation counting relative to control,Other,21885289.0,
1422,614244,1,4,,103348651,6197,Active,,,,,Inhibition of chitin synthase in germinated Mucor mucedo IFO 7684 assessed as incorporation of GlcNAc from [14C]-UDP-GlcNAc into acid-insoluble fractions at 0.36 mM after 60 mins by liquid scintillation counting,Other,21885289.0,
1423,617986,3,4,,103348651,6197,Active,,,1.1,IC50,Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay,Confirmatory,21899268.0,
1424,617987,3,2,,103348651,6197,Active,,,3.6,IC50,Cytotoxicity against human AGS cells after 48 hrs by MTT assay,Confirmatory,21899268.0,
1425,617988,3,2,,103348651,6197,Active,,,12.8,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,21899268.0,
1426,617989,3,2,,103348651,6197,Active,,,1.2,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,21899268.0,
1427,617990,3,2,,103348651,6197,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21899268.0,
1428,617993,1,4,,103348651,6197,Active,,,,,Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay,Other,21899268.0,
1429,623877,1,1,,56463698,6197,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1430,623901,1,1,,56463698,6197,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1431,624037,1,3,,56463698,6197,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1432,624038,1,3,,56463698,6197,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1433,624040,1,3,,56463698,6197,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1434,624125,1,4,,56463698,6197,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1435,624126,1,3,,56463698,6197,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1436,624127,1,2,,56463698,6197,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1437,624132,1,1,,56463698,6197,Active,,,0.345,AC50_uM,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1438,624133,1,1,,56463698,6197,Active,,,0.695,AC50_uM,Shn3: Dual-Go Shn3RL cells Measured in Cell-Based System Using Plate Reader - 2134-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1439,624134,1,1,,56463698,6197,Inactive,,,,AC50_uM,Shn3: Cytotox assay Measured in Cell-Based System Using Plate Reader - 2134-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1440,624156,1,1,,85788478,6197,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1441,624167,1,1,,56463698,6197,Inactive,78486550.0,171071.0,1.01,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1442,624167,1,1,4.0,56463698,6197,Active,78486550.0,171071.0,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1443,624167,1,1,5.0,56463698,6197,Unspecified,78486550.0,171071.0,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1444,624167,1,1,6.0,56463698,6197,Unspecified,78486550.0,171071.0,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1445,624167,1,1,7.0,56463698,6197,Active,,,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1446,624167,1,1,8.0,56463698,6197,Unspecified,,,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1447,624167,1,1,9.0,56463698,6197,Unspecified,,,,IC50_PEG-3_Mean,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,Confirmatory,,
1448,624168,1,1,,56463698,6197,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1449,624169,1,1,,56463698,6197,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1450,624170,1,1,,56463698,6197,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1451,624171,1,1,,56463698,6197,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1452,624172,1,1,,56463698,6197,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1453,624173,1,3,,56463698,6197,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1454,624178,1,1,,56463698,6197,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1455,624202,1,1,,56463698,6197,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1456,624204,1,2,,56463698,6197,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1457,624246,1,1,,56463698,6197,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1458,624256,1,2,,56463698,6197,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1459,624263,1,1,,56463698,6197,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1460,624263,1,1,,56463698,6197,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1461,624267,1,2,,56463698,6197,Active,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1462,624267,1,2,,56463698,6197,Active,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1463,624268,1,3,,56463698,6197,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1464,624288,1,1,,56463698,6197,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1465,624296,1,1,,56463698,6197,Inconclusive,7705682.0,51053.0,0.4611,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1466,624297,1,1,,56463698,6197,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1467,624304,1,2,,56463698,6197,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1468,624330,1,2,,56463698,6197,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1469,624344,1,1,,56463698,6197,Inactive,90421313.0,1080.0,0.46,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1470,624344,1,1,1.0,56463698,6197,Active,90421313.0,1080.0,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1471,624344,1,1,2.0,56463698,6197,Unspecified,90421313.0,1080.0,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1472,624344,1,1,3.0,56463698,6197,Unspecified,90421313.0,1080.0,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1473,624344,1,1,4.0,56463698,6197,Active,,,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1474,624344,1,1,5.0,56463698,6197,Unspecified,,,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1475,624344,1,1,6.0,56463698,6197,Unspecified,,,,IC50_CF-PAF_Mean,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,Confirmatory,,
1476,624349,1,2,,92124468,6197,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1477,624349,1,2,,92307580,6197,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1478,624349,1,2,,121363537,6197,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1479,624352,1,1,,56463698,6197,Active,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1480,624354,1,1,,56463698,6197,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1481,624370,1,2,,56463698,6197,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based high throughput confirmation assay for inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1482,624370,1,2,,56463698,6197,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based high throughput confirmation assay for inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1483,624371,1,2,,56463698,6197,Inactive,114881106.0,4290808.0,,,Counterscreen for inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and receptor-interacting serine-threonine kinase 2 (RIPK2): Fluorescence-based cell-based high throughput assay to identify non-selective inhibitors of the beta-lactamase enzyme (BLA),Screening,,
1484,624377,1,1,,103076162,6197,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1485,624378,1,1,,56463698,6197,Active,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput confirmation assay for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1486,624379,1,1,,56463698,6197,Active,9629429.0,,,,"Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): Luminescence-based cell-based high throughput screening assay to identify agonists of the Herpes Virus Virion Protein 16 (VP16)",Screening,,
1487,624405,1,1,,56463698,6197,Active,,,0.16,AbsAC40_uM,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Other_Dose_CherryPick_Activity,Confirmatory,,
1488,624414,1,1,,56463698,6197,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1489,624415,1,2,,56463698,6197,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1490,624416,1,1,,103076162,6197,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1491,624417,1,1,,56463698,6197,Active,1724069.0,2740.0,0.7943,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1492,624418,1,1,,56463698,6197,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1493,624463,1,1,,56463698,6197,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1494,624464,1,1,,56463698,6197,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1495,624465,1,1,,56463698,6197,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1496,624466,1,3,,103076162,6197,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1497,624467,1,1,,103076162,6197,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1498,624483,1,1,,56463698,6197,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1499,625144,5,5,,103348651,6197,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1500,625145,4,7,,103348651,6197,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1501,625146,5,5,,103348651,6197,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1502,625147,4,7,,103348651,6197,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1503,625148,4,7,,103348651,6197,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1504,625149,4,7,,103348651,6197,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1505,625150,5,5,,103348651,6197,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1506,625151,4,7,,103348651,6197,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1507,625152,4,7,,103348651,6197,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1508,625153,4,7,,103348651,6197,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1509,625154,4,7,,103348651,6197,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1510,625155,4,7,,103348651,6197,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1511,625156,1,9,,103348651,6197,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1512,625157,6,2,,103348651,6197,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1513,625158,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1514,625159,5,5,,103348651,6197,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1515,625160,1,9,,103348651,6197,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1516,625161,4,7,,103348651,6197,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1517,625162,4,7,,103348651,6197,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1518,625163,4,7,,103348651,6197,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1519,625164,1,6,,103348651,6197,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1520,625165,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1521,625166,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1522,625167,5,5,,103348651,6197,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1523,625168,4,7,,103348651,6197,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1524,625169,1,6,,103348651,6197,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1525,625170,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1526,625171,4,7,,103348651,6197,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1527,625172,4,7,,103348651,6197,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1528,625173,5,5,,103348651,6197,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1529,625174,5,5,,103348651,6197,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1530,625175,5,5,,103348651,6197,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1531,625176,1,9,,103348651,6197,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1532,625177,5,5,,103348651,6197,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1533,625178,5,5,,103348651,6197,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1534,625179,1,9,,103348651,6197,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1535,625180,5,5,,103348651,6197,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1536,625181,5,5,,103348651,6197,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1537,625182,5,5,,103348651,6197,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1538,625183,5,5,,103348651,6197,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1539,625184,5,5,,103348651,6197,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1540,625185,5,5,,103348651,6197,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1541,625186,5,5,,103348651,6197,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1542,625187,5,5,,103348651,6197,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1543,625188,1,9,,103348651,6197,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1544,625189,1,7,,103348651,6197,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1545,625190,4,5,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1546,625191,4,7,,103348651,6197,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1547,625192,4,7,,103348651,6197,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1548,625193,5,5,,103348651,6197,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1549,625194,4,7,,103348651,6197,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1550,625195,4,7,,103348651,6197,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1551,625196,5,6,,103348651,6197,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1552,625197,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1553,625198,4,7,,103348651,6197,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1554,625199,4,7,,103348651,6197,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1555,625200,4,7,,103348651,6197,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1556,625201,4,7,,103348651,6197,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1557,625202,4,7,,103348651,6197,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1558,625203,4,7,,103348651,6197,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1559,625204,4,7,,103348651,6197,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1560,625205,4,7,,103348651,6197,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1561,625206,4,7,,103348651,6197,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1562,625207,4,7,,103348651,6197,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1563,625208,5,5,,103348651,6197,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1564,625209,4,7,,103348651,6197,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1565,625210,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1566,625211,1,6,,103348651,6197,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1567,625212,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1568,625213,4,7,,103348651,6197,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1569,625214,1,9,,103348651,6197,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1570,625215,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1571,625216,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1572,625217,4,7,,103348651,6197,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1573,625218,4,7,,103348651,6197,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1574,625219,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1575,625220,4,7,,103348651,6197,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1576,625221,4,7,,103348651,6197,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1577,625222,4,7,,103348651,6197,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1578,625223,4,7,,103348651,6197,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1579,625224,3,4,,103348651,6197,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1580,625225,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1581,625226,4,7,,103348651,6197,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1582,625227,4,7,,103348651,6197,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1583,625228,4,7,,103348651,6197,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1584,625229,5,5,,103348651,6197,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1585,625230,1,6,,103348651,6197,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1586,625231,4,7,,103348651,6197,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1587,625232,1,9,,103348651,6197,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1588,625233,4,7,,103348651,6197,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1589,625234,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1590,625235,4,7,,103348651,6197,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1591,625236,5,5,,103348651,6197,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1592,625237,4,7,,103348651,6197,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1593,625238,4,7,,103348651,6197,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1594,625239,4,7,,103348651,6197,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1595,625240,1,9,,103348651,6197,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1596,625241,4,7,,103348651,6197,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1597,625242,4,7,,103348651,6197,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1598,625243,5,5,,103348651,6197,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1599,625244,5,5,,103348651,6197,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1600,625245,5,5,,103348651,6197,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1601,625246,1,9,,103348651,6197,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1602,625247,5,5,,103348651,6197,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1603,625248,5,5,,103348651,6197,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1604,625249,5,5,,103348651,6197,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1605,625250,5,5,,103348651,6197,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1606,625251,5,5,,103348651,6197,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1607,625252,4,7,,103348651,6197,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1608,625253,4,7,,103348651,6197,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1609,625254,4,7,,103348651,6197,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1610,625255,4,7,,103348651,6197,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1611,625256,4,7,,103348651,6197,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1612,625257,4,7,,103348651,6197,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1613,625258,4,7,,103348651,6197,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1614,625259,4,7,,103348651,6197,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1615,625260,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1616,625261,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1617,625262,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1618,625263,4,7,,103348651,6197,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1619,625264,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1620,625265,1,6,,103348651,6197,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1621,625266,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1622,625267,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1623,625268,4,2,,103348651,6197,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1624,625268,4,2,,103348651,6197,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1625,625268,4,2,,103348651,6197,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1626,625268,4,2,,103348651,6197,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1627,625269,4,7,,103348651,6197,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1628,625270,4,7,,103348651,6197,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1629,625271,5,5,,103348651,6197,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1630,625272,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1631,625273,4,6,,103348651,6197,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1632,625274,1,6,,103348651,6197,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1633,625275,3,4,,103348651,6197,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1634,651550,1,1,,56463698,6197,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1635,651560,1,1,,56463698,6197,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1636,651602,1,1,,103076162,6197,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1637,651602,1,1,,103076162,6197,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1638,651602,1,1,,103076162,6197,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1639,651611,1,1,,56463698,6197,Active,,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify nonselective inhibitors of the Steroidogenic acute regulatory protein (StAR) promoter or luminescence assay artifacts,Screening,,
1640,651613,1,1,,56463698,6197,Active,4504343.0,2494.0,,,Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1641,651614,1,1,,56463698,6197,Active,20070193.0,2516.0,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inverse agonists of the Steroidogenic Factor 1 Nuclear Receptor (SF1; NR5A1),Screening,,
1642,651615,1,1,,56463698,6197,Active,9629429.0,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
1643,651631,4,1,,144207129,6197,Active,269849759.0,7157.0,11.8832,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1644,651631,4,1,,144208356,6197,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1645,651632,4,1,,144207129,6197,Inactive,296439460.0,79915.0,0.3349,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1646,651632,4,1,,144208356,6197,Inactive,296439460.0,79915.0,0.1526,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1647,651633,4,1,,144207129,6197,Inconclusive,,,0.5308,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1648,651633,4,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1649,651634,4,1,,144207129,6197,Active,,,1.3333,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1650,651634,4,1,,144208356,6197,Active,,,0.2714,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1651,651635,1,3,,56463698,6197,Inconclusive,171543895.0,6311.0,1.122,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1652,651636,1,1,,56463698,6197,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1653,651640,1,1,,103076162,6197,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1654,651644,1,1,,56463698,6197,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1655,651647,1,1,,56463698,6197,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1656,651654,1,1,,56463698,6197,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1657,651658,1,1,,103076162,6197,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1658,651661,2,1,,103076162,6197,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1659,651687,1,1,,56463698,6197,Active,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1660,651699,1,1,,56463698,6197,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1661,651699,1,1,,56463698,6197,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1662,651702,1,2,,56463698,6197,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1663,651710,1,1,,103076162,6197,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1664,651711,2,1,,103076162,6197,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1665,651718,1,2,,103076162,6197,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1666,651719,1,2,,103076162,6197,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1667,651723,1,1,,56463698,6197,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1668,651724,1,1,,56463698,6197,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1669,651725,1,1,,56463698,6197,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1670,651741,1,1,,17389082,6197,Inconclusive,20149576.0,4780.0,94.3918,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1671,651741,1,1,,17389083,6197,Inconclusive,20149576.0,4780.0,33.4915,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1672,651741,1,1,,124883129,6197,Inconclusive,20149576.0,4780.0,48.5577,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1673,651743,1,1,,17389082,6197,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1674,651743,1,1,,17389083,6197,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1675,651743,1,1,,26752000,6197,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1676,651749,1,1,,17389082,6197,Inconclusive,34577122.0,4790.0,0.5012,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1677,651749,1,1,,17389083,6197,Inconclusive,34577122.0,4790.0,0.0891,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1678,651749,1,1,,26752000,6197,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1679,651751,1,1,,17389082,6197,Inactive,5702233.0,84385.0,63.0957,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1680,651751,1,1,,17389083,6197,Inactive,5702233.0,84385.0,56.2341,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1681,651751,1,1,,26752000,6197,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1682,651754,1,1,,17389082,6197,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1683,651754,1,1,,17389083,6197,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1684,651755,1,1,,17389082,6197,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1685,651755,1,1,,17389083,6197,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1686,651757,1,1,,17389082,6197,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1687,651757,1,1,,17389083,6197,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1688,651758,1,1,,17389082,6197,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1689,651758,1,1,,17389083,6197,Inconclusive,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1690,651768,1,2,,56463698,6197,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1691,651777,1,1,,17389082,6197,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1692,651777,1,1,,17389083,6197,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1693,651777,1,1,,26752000,6197,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1694,651778,1,1,,17389082,6197,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1695,651778,1,1,,17389083,6197,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1696,651778,1,1,,26752000,6197,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1697,651800,1,1,,103076162,6197,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1698,651802,1,1,,17389082,6197,Active,49066040.0,6097.0,0.1496,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1699,651802,1,1,,17389083,6197,Active,49066040.0,6097.0,0.2371,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1700,651819,1,1,,56463698,6197,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1701,651820,1,1,,56463698,6197,Active,,,1.2589,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1702,651821,2,4,,103076162,6197,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1703,651838,1,1,,17389082,6197,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1704,651838,1,1,,17389083,6197,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1705,651838,1,1,,26752000,6197,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1706,651838,1,1,1.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1707,651838,1,1,1.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1708,651838,1,1,1.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1709,651838,1,1,2.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1710,651838,1,1,2.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1711,651838,1,1,2.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1712,651838,1,1,3.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1713,651838,1,1,3.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1714,651838,1,1,3.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1715,651838,1,1,4.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1716,651838,1,1,4.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1717,651838,1,1,4.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1718,651838,1,1,5.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1719,651838,1,1,5.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1720,651838,1,1,5.0,26752000,6197,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1721,651838,1,1,6.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1722,651838,1,1,6.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1723,651838,1,1,6.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1724,651838,1,1,7.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1725,651838,1,1,7.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1726,651838,1,1,7.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1727,651838,1,1,8.0,17389082,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1728,651838,1,1,8.0,17389083,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1729,651838,1,1,8.0,26752000,6197,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1730,651957,1,1,,103076162,6197,Active,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1731,651958,1,1,,103076162,6197,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1732,651965,1,1,,56463698,6197,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1733,651999,1,1,,56463698,6197,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1734,652007,1,1,,103076162,6197,Active,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
1735,652008,1,1,,103076162,6197,Active,5729858.0,10499.0,,,Luminescence-based cell-based high throughput confirmation assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1736,652010,1,1,,103076162,6197,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1737,652017,1,1,,103076162,6197,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1738,652025,1,1,,56463698,6197,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1739,652039,1,1,,103076162,6197,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1740,652048,1,2,,56463698,6197,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1741,652048,1,2,,144207129,6197,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1742,652051,1,1,,56463698,6197,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1743,652051,1,1,,144207129,6197,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1744,652054,1,1,,56463698,6197,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1745,652067,1,4,,103076162,6197,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1746,652104,1,1,,56463698,6197,Inactive,20140568.0,23435.0,0.7079,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1747,652105,1,1,,56463698,6197,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1748,652106,1,1,,56463698,6197,Inactive,586067.0,6622.0,1.5849,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1749,652126,1,3,,103076162,6197,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1750,652162,2,1,,103076162,6197,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1751,652163,1,1,,103076162,6197,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1752,652197,1,1,,103076162,6197,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1753,652257,1,1,,103076162,6197,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1754,656845,2,3,,103348651,6197,Active,,,0.26,IC50,Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay,Confirmatory,22437110.0,
1755,658951,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Candida albicans 155965 at 100 mg/ml after 48 hrs by agar-well diffusion technique,Other,22464424.0,
1756,658952,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Saccharomyces cerevisiae 156250 at 100 mg/ml after 48 hrs by agar-well diffusion technique,Other,22464424.0,
1757,679178,1,8,,103348651,6197,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,9328323.0,
1758,679794,1,7,,103348651,6197,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Northern blot in vitro, nonparenchymal ral liver epithelial cells",Other,8630083.0,
1759,685500,2,2,,103348651,6197,Unspecified,,,100.0,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
1760,685501,2,2,,103348651,6197,Active,,,0.047,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
1761,686940,1,1,,103076162,6197,Active,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1762,686964,1,1,,103076162,6197,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1763,686970,1,2,,56463698,6197,Active,49168486.0,3417.0,0.7308,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1764,686971,1,2,,56463698,6197,Active,,,0.3663,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1765,686977,2,1,,49698641,6197,Inconclusive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1766,686978,1,1,,56463698,6197,Active,79154014.0,55775.0,0.1636,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1767,686978,1,1,,124883128,6197,Active,79154014.0,55775.0,0.1189,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1768,686978,1,1,,144207129,6197,Active,79154014.0,55775.0,0.0596,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1769,686979,1,1,,56463698,6197,Active,79154014.0,55775.0,0.1636,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1770,686979,1,1,,124883128,6197,Active,79154014.0,55775.0,0.1496,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1771,686979,1,1,,144207129,6197,Active,79154014.0,55775.0,0.0473,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1772,686996,1,1,,103076162,6197,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1773,687007,1,2,,103076162,6197,Inactive,9629429.0,,,,Counterscreen for antagonists of COUP-TFII (NR2F2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
1774,687008,1,1,,103076162,6197,Active,14149746.0,7026.0,,,Luminescence-based cell-based high throughput confirmation assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1775,687014,1,1,,103076162,6197,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1776,687016,1,1,,103076162,6197,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1777,694135,1,2,,103348651,6197,Unspecified,,,,,Inhibition of protein synthesis in Trypanosoma brucei assessed as reduction in [3H]L-histidine incorporation into proteins incubated for 4 hrs by scintillation counting,Other,22720744.0,
1778,697852,1,7,,103348651,6197,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1779,697853,1,7,,103348651,6197,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1780,716165,1,2,,103348651,6197,Active,,,,,Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis,Other,22607231.0,
1781,720504,1,1,,56463698,6197,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1782,720508,1,1,,103076162,6197,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1783,720509,1,1,,103076162,6197,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1784,720511,1,1,,103076162,6197,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1785,720513,1,1,,56463698,6197,Inactive,,,,AbsAC40_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_Dose_CherryPick_Activity_Set6,Confirmatory,,
1786,720514,1,1,,56463698,6197,Active,,,2.23,AC50_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1787,720516,2,1,,144207129,6197,Inconclusive,296439460.0,79915.0,0.694386,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1788,720516,2,1,,144208356,6197,Inconclusive,296439460.0,79915.0,0.251344,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1789,720522,1,1,,56463698,6197,Inactive,122893032.0,,,Potency,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,Confirmatory,,
1790,720523,1,1,,56463698,6197,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,Confirmatory,,
1791,720524,1,1,,56463698,6197,Active,224028257.0,4780.0,5.8048,Potency,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Confirmatory,,
1792,720532,1,1,,124883128,6197,Active,420597.0,,2.8184,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1793,720532,1,1,,144207129,6197,Active,420597.0,,3.1623,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1794,720533,1,1,,124883128,6197,Active,,,6.3096,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1795,720533,1,1,,144207129,6197,Active,,,2.8184,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1796,720542,1,2,,56463698,6197,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1797,720543,1,1,,103076162,6197,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1798,720547,1,1,,103076162,6197,Inactive,9629429.0,,85.421,IC50,Counterscreen for inhibitors of COUP-TFII (NR2F2): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Confirmatory,,
1799,720548,1,1,,103076162,6197,Active,14149746.0,7026.0,1.315,IC50,Luminescence-based cell-based high throughput dose response assay to identify inhibitors of COUP-TFII (NR2F2),Confirmatory,,
1800,720551,1,2,,56463698,6197,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1801,720552,2,1,,144207129,6197,Active,269849759.0,7157.0,11.8832,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1802,720552,2,1,,144208356,6197,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1803,720553,1,2,,56463698,6197,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1804,720579,2,1,,56463698,6197,Active,222762.0,3707576.0,0.3162,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1805,720580,1,1,,56463698,6197,Active,222762.0,3707576.0,0.2818,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1806,720582,1,1,,103076162,6197,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1807,720596,1,1,,103076162,6197,Active,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1808,720634,2,1,,144207129,6197,Inactive,,,0.5956,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1809,720634,2,1,,144208356,6197,Inactive,,,17.1239,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1810,720635,2,1,,144207129,6197,Inconclusive,,,0.5956,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1811,720635,2,1,,144208356,6197,Inconclusive,,,0.10800000000000001,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1812,720636,1,1,,17389082,6197,Inactive,20149576.0,4780.0,10.5909,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1813,720636,1,1,,17389083,6197,Inactive,20149576.0,4780.0,42.1632,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1814,720636,1,1,,124883129,6197,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1815,720637,2,1,,144207129,6197,Inconclusive,,,0.668242,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1816,720637,2,1,,144208356,6197,Inconclusive,,,0.215577,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1817,720641,1,2,,92307580,6197,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1818,720647,1,2,,103076162,6197,Active,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1819,720648,1,1,,103076162,6197,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1820,720652,1,1,,17389082,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1821,720652,1,1,,17389083,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1822,720653,1,1,,17389082,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1823,720653,1,1,,17389083,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1824,720653,1,1,,26752000,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1825,720659,1,1,,17389082,6197,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1826,720659,1,1,,17389083,6197,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1827,720659,1,1,,26752000,6197,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1828,720674,2,2,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1829,720674,2,2,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1830,720675,2,2,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1831,720675,2,2,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1832,720678,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1833,720678,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1834,720679,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1835,720679,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1836,720680,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1837,720680,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1838,720681,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1839,720681,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1840,720682,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1841,720682,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1842,720683,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1843,720683,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1844,720684,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1845,720684,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1846,720685,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1847,720685,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1848,720686,2,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1849,720686,2,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1850,720687,2,2,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1851,720687,2,2,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1852,720691,4,1,,144207129,6197,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1853,720691,4,1,,144208356,6197,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1854,720692,3,1,,144207129,6197,Active,311348376.0,2908.0,4.7716,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1855,720692,3,1,,144208356,6197,Active,311348376.0,2908.0,12.2321,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1856,720693,3,1,,144207129,6197,Inconclusive,,,0.4253,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1857,720693,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1858,720700,1,4,,103076162,6197,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1859,720702,1,1,,103076162,6197,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1860,720704,1,4,,103076162,6197,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1861,720706,1,2,,103076162,6197,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1862,720707,1,2,,56463698,6197,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1863,720708,1,2,,56463698,6197,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1864,720709,1,2,,56463698,6197,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1865,720711,1,2,,56463698,6197,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1866,720717,1,3,,92124468,6197,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1867,720717,1,3,,92125866,6197,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1868,720717,1,3,,92307580,6197,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1869,720719,2,1,,144207129,6197,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1870,720719,2,1,,144208356,6197,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1871,720725,2,1,,144207129,6197,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1872,720725,2,1,,144208356,6197,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1873,725041,1,3,,103348651,6197,Unspecified,,,128.31,IC50,Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1874,725042,1,3,,103348651,6197,Active,,,40.6,IC50,Cytotoxicity against human PA1 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1875,725043,1,2,,103348651,6197,Unspecified,,,57.12,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1876,725044,1,2,,103348651,6197,Unspecified,,,60.1,IC50,Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1877,725045,1,3,,103348651,6197,Unspecified,,,54.13,IC50,Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1878,725046,1,3,,103348651,6197,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
1879,725047,1,2,,103348651,6197,Unspecified,,,65.13,IC50,Cytotoxicity against human T47D cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
1880,725048,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
1881,725049,1,3,,103348651,6197,Unspecified,,,,,Cytotoxicity against human PA1 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
1882,725050,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against human NCI-H522 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
1883,725051,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against human T47D cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
1884,735973,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Botrytis fabae after 48 hrs by microdilution susceptibility test,Other,23318903.0,
1885,735974,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum after 48 hrs by microdilution susceptibility test,Other,23318903.0,
1886,735975,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs by microdilution susceptibility test,Other,23318903.0,
1887,735976,3,1,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Escherichia coli after 24 hrs by microdilution susceptibility test,Other,23318903.0,
1888,735977,3,1,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Bacillus subtilis after 24 hrs by microdilution susceptibility test,Other,23318903.0,
1889,735978,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Bacillus thuringiensis after 24 hrs by by microdilution susceptibility test,Other,23318903.0,
1890,735979,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Botrytis fabae at 1 mg/mL after 48 hrs by agar disc diffusion method,Other,23318903.0,
1891,735980,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum at 1 mg/mL after 48 hrs by agar disc diffusion method,Other,23318903.0,
1892,735981,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Pseudomonas aeruginosa at 1 mg/mL after 24 hrs by agar disc diffusion method,Other,23318903.0,
1893,735982,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Escherichia coli at 1 mg/mL after 24 hrs by agar disc diffusion method,Other,23318903.0,
1894,735983,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Bacillus thuringiensis at 1 mg/mL after 24 hrs by agar disc diffusion method,Other,23318903.0,
1895,736388,1,2,,103348651,6197,Inconclusive,,,,,Antimicrobial activity against Bacillus subtilis at 1 mg/mL after 24 hrs by agar disc diffusion method,Other,23318903.0,
1896,739246,1,2,,103348651,6197,Active,,,,,Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay,Other,23434131.0,
1897,739247,1,2,,103348651,6197,Active,,,,,Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay,Other,23434131.0,
1898,743012,3,1,,144207129,6197,Active,,,0.0596,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1899,743012,3,1,,144208356,6197,Active,,,0.10800000000000001,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1900,743014,3,1,,144207129,6197,Active,,,0.1188,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1901,743014,3,1,,144208356,6197,Active,,,0.0608,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1902,743015,3,1,,144207129,6197,Active,,,0.1333,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1903,743015,3,1,,144208356,6197,Active,,,0.1212,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1904,743033,3,1,,144207129,6197,Active,,,0.379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1905,743033,3,1,,144208356,6197,Active,,,0.0972,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1906,743035,2,1,,144207129,6197,Active,124375976.0,367.0,1.0682,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1907,743035,2,1,,144208356,6197,Active,124375976.0,367.0,0.434,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1908,743036,2,1,,144207129,6197,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1909,743036,2,1,,144208356,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1910,743040,3,1,,144207129,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1911,743040,3,1,,144208356,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1912,743041,3,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1913,743041,3,1,,144208356,6197,Inconclusive,,,0.6076,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1914,743042,3,1,,144207129,6197,Active,124375976.0,367.0,0.2985,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1915,743042,3,1,,144208356,6197,Active,124375976.0,367.0,0.2156,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1916,743053,2,1,,144207129,6197,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1917,743053,2,1,,144208356,6197,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1918,743054,2,1,,144207129,6197,Active,124375976.0,367.0,0.390482,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1919,743054,2,1,,144208356,6197,Active,124375976.0,367.0,0.20745999999999998,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1920,743063,2,1,,144207129,6197,Inconclusive,124375976.0,367.0,1.15344,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1921,743063,2,1,,144208356,6197,Inconclusive,124375976.0,367.0,0.284555,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1922,743064,3,1,,144207129,6197,Active,,,0.2371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1923,743064,3,1,,144208356,6197,Inconclusive,,,0.6076,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1924,743065,3,1,,144207129,6197,Active,399498506.0,24831.0,0.0668,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1925,743065,3,1,,144208356,6197,Active,399498506.0,24831.0,0.0608,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1926,743066,3,1,,144207129,6197,Inconclusive,399498506.0,24831.0,0.2113,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1927,743066,3,1,,144208356,6197,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1928,743067,2,1,,144207129,6197,Active,399498506.0,24831.0,0.0595572,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1929,743067,2,1,,144208356,6197,Inconclusive,399498506.0,24831.0,0.0328802,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1930,743069,2,1,,144207129,6197,Inconclusive,348019627.0,2099.0,5.3538,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1931,743069,2,1,,144208356,6197,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1932,743074,2,1,,144207129,6197,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1933,743074,2,1,,144208356,6197,Inconclusive,,,27.3842,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1934,743075,2,1,,144207129,6197,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1935,743075,2,1,,144208356,6197,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1936,743077,2,1,,144207129,6197,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1937,743077,2,1,,144208356,6197,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1938,743078,2,1,,144207129,6197,Inconclusive,348019627.0,2099.0,4.77156,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1939,743078,2,1,,144208356,6197,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1940,743079,3,1,,144207129,6197,Inconclusive,348019627.0,2099.0,0.9439,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1941,743079,3,1,,144208356,6197,Inconclusive,348019627.0,2099.0,0.6817,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1942,743080,3,1,,144207129,6197,Active,348019627.0,2099.0,0.6682,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1943,743080,3,1,,144208356,6197,Active,348019627.0,2099.0,0.5415,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1944,743081,3,1,,144207129,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1945,743081,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1946,743083,3,1,,144207129,6197,Active,119597822.0,1588.0,0.7498,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1947,743083,3,1,,144208356,6197,Active,119597822.0,1588.0,0.3834,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1948,743084,3,1,,144207129,6197,Inconclusive,,,14.9601,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1949,743084,3,1,,144208356,6197,Inconclusive,,,6.8171,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1950,743085,3,1,,144207129,6197,Active,51095037.0,196.0,0.6682,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1951,743085,3,1,,144208356,6197,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1952,743086,3,1,,144207129,6197,Inconclusive,,,1.1883,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1953,743086,3,1,,144208356,6197,Inconclusive,,,1.0804,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1954,743091,2,1,,144207129,6197,Active,348019627.0,2099.0,0.5108189999999999,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1955,743091,2,1,,144208356,6197,Active,348019627.0,2099.0,0.293045,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1956,743094,3,1,,144207129,6197,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1957,743094,3,1,,144208356,6197,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1958,743122,2,1,,144207129,6197,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1959,743122,2,1,,144208356,6197,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1960,743126,1,1,,103076162,6197,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1961,743139,2,1,,144207129,6197,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1962,743139,2,1,,144208356,6197,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1963,743140,2,1,,144207129,6197,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1964,743140,2,1,,144208356,6197,Inconclusive,216409692.0,5468.0,24.4062,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1965,743191,3,1,,144208356,6197,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1966,743191,3,1,,170466349,6197,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1967,743194,3,1,,144208356,6197,Inconclusive,,,0.434,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1968,743194,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1969,743199,2,1,,144208356,6197,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1970,743199,2,1,,170466349,6197,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1971,743200,1,2,,103076162,6197,Active,4506113.0,5621.0,,,TRFRET-based cell-based high throughput confirmation assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1972,743201,1,3,,103076162,6197,Active,4506113.0,5621.0,,,Counterscreen for inhibitors of cell surface Prion Protein (PrPc): Luminescence-based cell-based high throughput assay to identify compounds that are cytotoxic to LD9 cells,Screening,,
1973,743202,4,1,,144208356,6197,Inconclusive,20149576.0,4780.0,12.1228,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1974,743202,4,1,,170466349,6197,Inconclusive,20149576.0,4780.0,0.0422,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1975,743203,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1976,743203,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1977,743209,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1978,743209,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1979,743210,4,1,,144208356,6197,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1980,743210,4,1,,170466349,6197,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1981,743211,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1982,743211,3,1,,170466349,6197,Inconclusive,,,11.8823,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1983,743212,3,1,,144208356,6197,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1984,743212,3,1,,170466349,6197,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1985,743213,3,1,,144208356,6197,Inconclusive,,,0.866,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1986,743213,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1987,743215,3,1,,144208356,6197,Inconclusive,216409690.0,5467.0,19.3865,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1988,743215,3,1,,170466349,6197,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1989,743217,3,1,,144208356,6197,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1990,743217,3,1,,170466349,6197,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1991,743218,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1992,743218,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1993,743219,3,1,,144208356,6197,Inconclusive,20149576.0,4780.0,3.16423,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1994,743219,3,1,,170466349,6197,Inconclusive,20149576.0,4780.0,0.334889,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1995,743220,3,1,,144208356,6197,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1996,743220,3,1,,170466349,6197,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1997,743221,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1998,743221,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1999,743222,3,1,,144208356,6197,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2000,743222,3,1,,170466349,6197,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2001,743223,3,1,,144208356,6197,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2002,743223,3,1,,170466349,6197,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2003,743224,3,1,,144208356,6197,Inconclusive,,,0.3868,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2004,743224,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2005,743225,3,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2006,743225,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2007,743226,2,1,,144208356,6197,Active,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2008,743226,2,1,,170466349,6197,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2009,743227,2,1,,144208356,6197,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2010,743227,2,1,,170466349,6197,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2011,743228,3,1,,144208356,6197,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2012,743228,3,1,,170466349,6197,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2013,743239,2,1,,144208356,6197,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2014,743239,2,1,,170466349,6197,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2015,743240,2,1,,144208356,6197,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2016,743240,2,1,,170466349,6197,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2017,743241,2,1,,144208356,6197,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2018,743241,2,1,,170466349,6197,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2019,743242,2,1,,144208356,6197,Active,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2020,743242,2,1,,170466349,6197,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2021,743244,1,1,,144207129,6197,Active,,,2.8184,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2022,743255,1,1,,56463698,6197,Inconclusive,118600387.0,7398.0,35.4813,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2023,743266,1,2,,56463698,6197,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2024,743269,1,1,,103076162,6197,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2025,743269,1,1,,103076162,6197,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2026,743279,1,2,,56463698,6197,Active,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2027,743287,1,1,,103076162,6197,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2028,743288,1,1,,17389082,6197,Inconclusive,,,0.631,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2029,743288,1,1,,17389083,6197,Active,,,0.1259,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2030,743288,1,1,,26752000,6197,Inconclusive,,,0.7943,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2031,743292,1,1,,17389082,6197,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2032,743292,1,1,,17389083,6197,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2033,743292,1,1,,26752000,6197,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2034,743322,2,1,,170466349,6197,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2035,743323,2,1,,170466349,6197,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2036,743324,2,1,,170466349,6197,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2037,743344,1,1,,174007022,6197,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2038,743345,1,1,,174007022,6197,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2039,743346,1,1,,174007022,6197,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2040,743347,1,1,,174007022,6197,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2041,743364,1,2,,174007022,6197,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (3D7) proliferation (acoustic dispense),Confirmatory,,
2042,743365,1,2,,174007022,6197,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (DD2) proliferation (acoustic dispense),Confirmatory,,
2043,743366,1,2,,174007022,6197,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (HB3) proliferation (acoustic dispense),Confirmatory,,
2044,743398,1,1,,103076162,6197,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2045,743417,1,1,,56463698,6197,Active,,,0.345,AC50_uM,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_Dose_DryPowder_Activity_Set2,Confirmatory,,
2046,751432,1,1,,103348651,6197,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as cell viability at 50 uM after 3 hrs,Other,23314048.0,
2047,816843,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/13,Other,,
2048,816844,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/13,Other,,
2049,816845,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/13,Other,,
2050,816846,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/13,Other,,
2051,816847,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/13,Other,,
2052,816848,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/13,Other,,
2053,816849,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/13,Other,,
2054,816850,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/13,Other,,
2055,816851,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/13,Other,,
2056,816852,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/13,Other,,
2057,816853,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/13,Other,,
2058,816854,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/13,Other,,
2059,816855,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/14,Other,,
2060,816856,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/14,Other,,
2061,816857,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/14,Other,,
2062,816858,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/14,Other,,
2063,816859,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/14,Other,,
2064,816860,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/14,Other,,
2065,816861,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/14,Other,,
2066,816862,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/14,Other,,
2067,816863,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/14,Other,,
2068,816864,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/14,Other,,
2069,816865,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/14,Other,,
2070,816866,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/14,Other,,
2071,816867,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/15,Other,,
2072,816868,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/15,Other,,
2073,816869,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/15,Other,,
2074,816870,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/15,Other,,
2075,816871,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/15,Other,,
2076,816872,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/15,Other,,
2077,816873,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/15,Other,,
2078,816874,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/15,Other,,
2079,816875,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/15,Other,,
2080,816876,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/15,Other,,
2081,816877,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/15,Other,,
2082,816878,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/15,Other,,
2083,817549,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/16,Other,,
2084,817550,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/16,Other,,
2085,817551,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/16,Other,,
2086,817552,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/16,Other,,
2087,817553,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/16,Other,,
2088,817554,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/16,Other,,
2089,817555,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/16,Other,,
2090,817556,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/16,Other,,
2091,817557,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/16,Other,,
2092,817558,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/16,Other,,
2093,818954,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/5,Other,,
2094,818955,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/5,Other,,
2095,818956,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/5,Other,,
2096,818957,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/5,Other,,
2097,818958,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/5,Other,,
2098,818959,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/5,Other,,
2099,818960,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/5,Other,,
2100,818961,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/5,Other,,
2101,818962,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/5,Other,,
2102,818963,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/5,Other,,
2103,818964,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/5,Other,,
2104,818965,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/5,Other,,
2105,818966,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/5,Other,,
2106,818967,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/5,Other,,
2107,818968,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/5,Other,,
2108,818969,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/5,Other,,
2109,818970,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/5,Other,,
2110,818971,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/6,Other,,
2111,818972,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/6,Other,,
2112,819640,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/6,Other,,
2113,819641,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/6,Other,,
2114,819642,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/6,Other,,
2115,819643,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/6,Other,,
2116,819644,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/6,Other,,
2117,819645,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/6,Other,,
2118,819646,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/6,Other,,
2119,819647,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/6,Other,,
2120,819648,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/6,Other,,
2121,819649,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/6,Other,,
2122,819650,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/6,Other,,
2123,819651,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/6,Other,,
2124,819652,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/6,Other,,
2125,819653,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/6,Other,,
2126,819654,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/6,Other,,
2127,819655,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/7,Other,,
2128,819656,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/7,Other,,
2129,819657,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/7,Other,,
2130,819658,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/7,Other,,
2131,819659,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/7,Other,,
2132,819660,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/7,Other,,
2133,819661,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/7,Other,,
2134,819662,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/7,Other,,
2135,819663,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/7,Other,,
2136,819664,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/7,Other,,
2137,819665,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/7,Other,,
2138,819666,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/7,Other,,
2139,819700,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/16,Other,,
2140,819701,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/16,Other,,
2141,821813,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/7,Other,,
2142,821814,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/7,Other,,
2143,821815,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/7,Other,,
2144,821816,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/7,Other,,
2145,821817,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/7,Other,,
2146,821818,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/8,Other,,
2147,821819,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/8,Other,,
2148,821820,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/8,Other,,
2149,821821,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/8,Other,,
2150,821822,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/8,Other,,
2151,822487,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/8,Other,,
2152,822488,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/8,Other,,
2153,822489,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/8,Other,,
2154,822490,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/8,Other,,
2155,822491,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/8,Other,,
2156,822492,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/8,Other,,
2157,822493,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/8,Other,,
2158,822494,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/8,Other,,
2159,822495,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/8,Other,,
2160,822496,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/8,Other,,
2161,822497,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/8,Other,,
2162,822498,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/8,Other,,
2163,822499,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/9,Other,,
2164,822500,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/9,Other,,
2165,822501,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/9,Other,,
2166,822502,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/9,Other,,
2167,822503,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/9,Other,,
2168,822504,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/9,Other,,
2169,822505,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/9,Other,,
2170,822506,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/9,Other,,
2171,822507,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/9,Other,,
2172,822508,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/9,Other,,
2173,822509,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/9,Other,,
2174,822510,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/9,Other,,
2175,822511,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/9,Other,,
2176,822512,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/9,Other,,
2177,822513,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/9,Other,,
2178,822514,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/9,Other,,
2179,822515,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/9,Other,,
2180,822516,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/10,Other,,
2181,822517,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/10,Other,,
2182,822518,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/10,Other,,
2183,822519,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/10,Other,,
2184,822520,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/10,Other,,
2185,822521,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/10,Other,,
2186,824672,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/10,Other,,
2187,825338,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/10,Other,,
2188,825339,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/10,Other,,
2189,825340,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/10,Other,,
2190,825341,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/10,Other,,
2191,825342,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/10,Other,,
2192,825343,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/10,Other,,
2193,825344,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/10,Other,,
2194,825345,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/10,Other,,
2195,825346,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/10,Other,,
2196,825347,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/10,Other,,
2197,825348,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/11,Other,,
2198,825349,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/11,Other,,
2199,825350,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/11,Other,,
2200,825351,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/11,Other,,
2201,825352,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/11,Other,,
2202,825353,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/11,Other,,
2203,825354,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/11,Other,,
2204,825355,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/11,Other,,
2205,825356,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/11,Other,,
2206,825357,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/11,Other,,
2207,825358,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/11,Other,,
2208,825359,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/11,Other,,
2209,825360,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/11,Other,,
2210,825361,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/11,Other,,
2211,825362,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/11,Other,,
2212,825363,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/11,Other,,
2213,825364,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/11,Other,,
2214,825365,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 454/12,Other,,
2215,825366,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 454/12,Other,,
2216,825367,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 454/12,Other,,
2217,825368,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 454/12,Other,,
2218,825369,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 454/12,Other,,
2219,825370,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 454/12,Other,,
2220,825371,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 454/12,Other,,
2221,825372,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 454/12,Other,,
2222,825373,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 454/12,Other,,
2223,825374,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 454/12,Other,,
2224,825375,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 454/12,Other,,
2225,825376,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 454/12,Other,,
2226,825377,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 454/12,Other,,
2227,825378,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 454/12,Other,,
2228,825379,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 454/12,Other,,
2229,825380,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 454/12,Other,,
2230,826047,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 454/12,Other,,
2231,848883,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/7,Other,,
2232,848884,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/7,Other,,
2233,848885,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/7,Other,,
2234,848886,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/7,Other,,
2235,848887,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/7,Other,,
2236,848888,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/7,Other,,
2237,849566,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/7,Other,,
2238,849567,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/7,Other,,
2239,849568,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/7,Other,,
2240,849569,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/7,Other,,
2241,849570,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/7,Other,,
2242,849571,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/8,Other,,
2243,849572,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/8,Other,,
2244,849573,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/8,Other,,
2245,849574,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/8,Other,,
2246,849575,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/8,Other,,
2247,849576,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/8,Other,,
2248,849577,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/8,Other,,
2249,849578,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/8,Other,,
2250,849579,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/8,Other,,
2251,849580,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/8,Other,,
2252,849581,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/8,Other,,
2253,849582,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/8,Other,,
2254,849583,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/8,Other,,
2255,849584,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/8,Other,,
2256,849585,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/8,Other,,
2257,849586,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/8,Other,,
2258,849587,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/8,Other,,
2259,849588,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/8,Other,,
2260,849589,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/8,Other,,
2261,849590,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/8,Other,,
2262,849591,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/8,Other,,
2263,849592,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/9,Other,,
2264,849593,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/9,Other,,
2265,849594,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/9,Other,,
2266,849595,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/9,Other,,
2267,849596,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/9,Other,,
2268,849597,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/9,Other,,
2269,849598,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/9,Other,,
2270,849599,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/9,Other,,
2271,849600,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/9,Other,,
2272,849601,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/9,Other,,
2273,849602,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/9,Other,,
2274,849603,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/9,Other,,
2275,849604,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/9,Other,,
2276,849605,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/9,Other,,
2277,849638,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/16,Other,,
2278,849639,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/16,Other,,
2279,849640,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/16,Other,,
2280,849641,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/16,Other,,
2281,849642,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/16,Other,,
2282,849643,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/16,Other,,
2283,849644,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/16,Other,,
2284,849645,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/16,Other,,
2285,849646,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/16,Other,,
2286,849647,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/16,Other,,
2287,849648,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/16,Other,,
2288,849649,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/16,Other,,
2289,849650,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/16,Other,,
2290,849651,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/16,Other,,
2291,849652,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/16,Other,,
2292,849653,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/16,Other,,
2293,849654,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/16,Other,,
2294,852445,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/9,Other,,
2295,852446,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/9,Other,,
2296,852447,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/9,Other,,
2297,852448,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/9,Other,,
2298,852449,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/9,Other,,
2299,852450,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/9,Other,,
2300,852451,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/9,Other,,
2301,852452,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/10,Other,,
2302,852453,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/10,Other,,
2303,852454,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/10,Other,,
2304,852455,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/10,Other,,
2305,852456,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/10,Other,,
2306,852457,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/10,Other,,
2307,852458,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/10,Other,,
2308,852459,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/10,Other,,
2309,852460,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/10,Other,,
2310,852461,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/10,Other,,
2311,852462,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/10,Other,,
2312,852463,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/10,Other,,
2313,852464,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/10,Other,,
2314,852465,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/10,Other,,
2315,852466,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/10,Other,,
2316,852467,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/10,Other,,
2317,852468,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/10,Other,,
2318,852469,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/10,Other,,
2319,852470,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/10,Other,,
2320,852471,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/10,Other,,
2321,852472,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/10,Other,,
2322,852473,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/11,Other,,
2323,852474,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/11,Other,,
2324,852475,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/11,Other,,
2325,852476,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/11,Other,,
2326,852477,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/11,Other,,
2327,852478,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/11,Other,,
2328,852479,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/11,Other,,
2329,852480,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/11,Other,,
2330,852481,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/11,Other,,
2331,852482,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/11,Other,,
2332,852483,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/11,Other,,
2333,852484,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/11,Other,,
2334,852485,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/11,Other,,
2335,852486,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/11,Other,,
2336,852487,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/11,Other,,
2337,853167,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/11,Other,,
2338,853168,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/11,Other,,
2339,853169,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/11,Other,,
2340,855298,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/5,Other,,
2341,855299,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/5,Other,,
2342,855300,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/5,Other,,
2343,855301,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/5,Other,,
2344,855302,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/5,Other,,
2345,855303,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/5,Other,,
2346,855333,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/11,Other,,
2347,855334,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/11,Other,,
2348,855335,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/11,Other,,
2349,855336,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/12,Other,,
2350,855337,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/12,Other,,
2351,855338,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/12,Other,,
2352,855339,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/12,Other,,
2353,855340,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/12,Other,,
2354,855341,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/12,Other,,
2355,855342,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/12,Other,,
2356,855343,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/12,Other,,
2357,855344,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/12,Other,,
2358,855345,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/12,Other,,
2359,855346,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/12,Other,,
2360,855347,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/12,Other,,
2361,855348,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/12,Other,,
2362,855349,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/12,Other,,
2363,855350,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/12,Other,,
2364,855351,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/12,Other,,
2365,855352,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/12,Other,,
2366,855353,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/12,Other,,
2367,855354,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/12,Other,,
2368,855355,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/12,Other,,
2369,855356,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/12,Other,,
2370,855357,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/13,Other,,
2371,855358,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/13,Other,,
2372,855359,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/13,Other,,
2373,855360,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/13,Other,,
2374,855361,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/13,Other,,
2375,855362,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/13,Other,,
2376,855363,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/13,Other,,
2377,855364,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/13,Other,,
2378,855365,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/13,Other,,
2379,855366,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/13,Other,,
2380,855367,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/13,Other,,
2381,856044,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/13,Other,,
2382,856045,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/13,Other,,
2383,856046,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/13,Other,,
2384,856047,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/13,Other,,
2385,856048,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/13,Other,,
2386,856049,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/13,Other,,
2387,856050,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/13,Other,,
2388,856051,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/13,Other,,
2389,856052,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/13,Other,,
2390,856053,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/13,Other,,
2391,857464,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/5,Other,,
2392,857465,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/5,Other,,
2393,857466,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/5,Other,,
2394,857467,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/5,Other,,
2395,857468,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/5,Other,,
2396,857469,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/5,Other,,
2397,857470,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/5,Other,,
2398,857471,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/5,Other,,
2399,857472,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/5,Other,,
2400,857473,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/5,Other,,
2401,857474,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/5,Other,,
2402,857475,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/5,Other,,
2403,857476,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/5,Other,,
2404,857477,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/5,Other,,
2405,858155,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/5,Other,,
2406,858156,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/6,Other,,
2407,858157,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/6,Other,,
2408,858158,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/6,Other,,
2409,858159,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/6,Other,,
2410,858160,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/6,Other,,
2411,858161,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/6,Other,,
2412,858162,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/6,Other,,
2413,858163,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/6,Other,,
2414,858164,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/6,Other,,
2415,858165,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/6,Other,,
2416,858166,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/6,Other,,
2417,858167,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/6,Other,,
2418,858168,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/6,Other,,
2419,858169,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/6,Other,,
2420,858170,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/6,Other,,
2421,858171,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/6,Other,,
2422,858172,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/6,Other,,
2423,858173,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/6,Other,,
2424,858174,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/6,Other,,
2425,858175,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/6,Other,,
2426,858176,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/6,Other,,
2427,858177,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/7,Other,,
2428,858178,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/7,Other,,
2429,858179,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/7,Other,,
2430,858180,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/7,Other,,
2431,858181,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/7,Other,,
2432,858182,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/7,Other,,
2433,858183,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/7,Other,,
2434,858184,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/7,Other,,
2435,858185,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/7,Other,,
2436,858186,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/7,Other,,
2437,858217,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/14,Other,,
2438,858218,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/14,Other,,
2439,858219,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/14,Other,,
2440,858220,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/14,Other,,
2441,858221,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/14,Other,,
2442,858222,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/14,Other,,
2443,858223,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/14,Other,,
2444,858224,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/14,Other,,
2445,858225,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/14,Other,,
2446,858226,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/14,Other,,
2447,858227,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/14,Other,,
2448,858228,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/14,Other,,
2449,858229,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/14,Other,,
2450,858230,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/14,Other,,
2451,858231,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/14,Other,,
2452,858232,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/14,Other,,
2453,858233,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/14,Other,,
2454,858234,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/14,Other,,
2455,858235,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/14,Other,,
2456,858236,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/14,Other,,
2457,858237,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/14,Other,,
2458,858238,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/15,Other,,
2459,858239,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/15,Other,,
2460,858240,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/15,Other,,
2461,858241,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/15,Other,,
2462,858242,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 454/15,Other,,
2463,858922,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 454/15,Other,,
2464,858923,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 454/15,Other,,
2465,858924,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 454/15,Other,,
2466,858925,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 454/15,Other,,
2467,858926,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 454/15,Other,,
2468,858927,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 454/15,Other,,
2469,858928,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 454/15,Other,,
2470,858929,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 454/15,Other,,
2471,858930,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 454/15,Other,,
2472,858931,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 454/15,Other,,
2473,858932,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 454/15,Other,,
2474,858933,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 454/15,Other,,
2475,858934,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 454/15,Other,,
2476,858935,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 454/15,Other,,
2477,858936,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 454/15,Other,,
2478,858937,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 454/15,Other,,
2479,858938,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 454/16,Other,,
2480,858939,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 454/16,Other,,
2481,858940,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 454/16,Other,,
2482,858941,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 454/16,Other,,
2483,936610,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030218,Other,,
2484,936611,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030218,Other,,
2485,936612,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030218,Other,,
2486,936613,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030218,Other,,
2487,936614,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030218,Other,,
2488,936615,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030218,Other,,
2489,936616,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030218,Other,,
2490,936617,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030218,Other,,
2491,936618,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030218,Other,,
2492,936619,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030218,Other,,
2493,936620,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030218,Other,,
2494,936621,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030218,Other,,
2495,937252,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030218,Other,,
2496,937253,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030218,Other,,
2497,937254,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030218,Other,,
2498,937255,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030218",Other,,
2499,937256,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030218,Other,,
2500,937257,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030218,Other,,
2501,937258,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030218,Other,,
2502,937259,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030218,Other,,
2503,937260,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030218,Other,,
2504,937261,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030218,Other,,
2505,937262,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030218,Other,,
2506,937263,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030218,Other,,
2507,937264,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030218,Other,,
2508,945277,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030218,Other,,
2509,945278,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030218,Other,,
2510,945279,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030218,Other,,
2511,945280,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030218,Other,,
2512,945281,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030218,Other,,
2513,945282,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030218,Other,,
2514,945283,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030218,Other,,
2515,945284,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030218,Other,,
2516,945285,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030218,Other,,
2517,945286,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030218,Other,,
2518,945287,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030218,Other,,
2519,945288,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030218,Other,,
2520,945289,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030218",Other,,
2521,953051,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030218,Other,,
2522,953052,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030218,Other,,
2523,953683,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030218,Other,,
2524,953684,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030218,Other,,
2525,953685,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030218,Other,,
2526,953686,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030218,Other,,
2527,953687,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030218,Other,,
2528,953688,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030218,Other,,
2529,953689,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030218,Other,,
2530,953690,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030218,Other,,
2531,953691,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030218,Other,,
2532,953692,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030218,Other,,
2533,953693,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030218,Other,,
2534,953694,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030218,Other,,
2535,953695,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030218,Other,,
2536,953696,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030218,Other,,
2537,953697,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030218,Other,,
2538,953698,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030218,Other,,
2539,953699,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030218,Other,,
2540,953700,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030218,Other,,
2541,953701,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030218,Other,,
2542,953702,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030218,Other,,
2543,953703,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030218,Other,,
2544,955642,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030218,Other,,
2545,955643,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030218,Other,,
2546,955644,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030218,Other,,
2547,955645,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030218,Other,,
2548,955646,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030218,Other,,
2549,955647,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030218,Other,,
2550,955648,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030218,Other,,
2551,955649,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030218,Other,,
2552,955650,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030218,Other,,
2553,955651,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030218,Other,,
2554,955652,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030218,Other,,
2555,955653,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030218,Other,,
2556,955654,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030218,Other,,
2557,955655,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030218,Other,,
2558,955656,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030218,Other,,
2559,977599,1,1,,103348651,6197,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2560,977602,1,2,,103348651,6197,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2561,998492,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S030218,Other,,
2562,998493,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030218",Other,,
2563,998494,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S030218",Other,,
2564,998495,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S030218",Other,,
2565,998496,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S030218",Other,,
2566,998497,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2567,998498,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030218",Other,,
2568,998499,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S030218",Other,,
2569,998500,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S030218",Other,,
2570,998501,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S030218",Other,,
2571,998502,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S030218",Other,,
2572,998503,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S030218,Other,,
2573,998504,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S030218",Other,,
2574,998505,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S030218,Other,,
2575,998506,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S030218",Other,,
2576,998507,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S030218",Other,,
2577,998508,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S030218",Other,,
2578,998509,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S030218",Other,,
2579,998510,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2580,998511,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S030218",Other,,
2581,998512,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S030218",Other,,
2582,998513,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S030218",Other,,
2583,998514,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030218",Other,,
2584,998515,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030218",Other,,
2585,998516,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S030218",Other,,
2586,998517,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S030218,Other,,
2587,998518,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030218",Other,,
2588,998519,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S030218",Other,,
2589,998520,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S030218",Other,,
2590,998521,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S030218",Other,,
2591,998522,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S030218",Other,,
2592,998523,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S030218",Other,,
2593,998524,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S030218",Other,,
2594,998525,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S030218",Other,,
2595,998526,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S030218",Other,,
2596,1000969,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S030218",Other,,
2597,1000970,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S030218",Other,,
2598,1000971,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S030218",Other,,
2599,1000972,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S030218",Other,,
2600,1000973,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S030218",Other,,
2601,1000974,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S030218,Other,,
2602,1000975,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S030218,Other,,
2603,1000976,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S030218",Other,,
2604,1000977,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S030218",Other,,
2605,1000978,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S030218",Other,,
2606,1000979,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S030218",Other,,
2607,1000980,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S030218",Other,,
2608,1000981,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S030218",Other,,
2609,1000982,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S030218",Other,,
2610,1000983,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S030218,Other,,
2611,1000984,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S030218",Other,,
2612,1000985,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030218",Other,,
2613,1000986,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S030218",Other,,
2614,1000987,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2615,1000988,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S030218",Other,,
2616,1000989,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S030218",Other,,
2617,1000990,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S030218,Other,,
2618,1000991,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030218",Other,,
2619,1000992,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S030218",Other,,
2620,1000993,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S030218",Other,,
2621,1000994,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S030218",Other,,
2622,1000995,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S030218",Other,,
2623,1000996,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S030218",Other,,
2624,1000997,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S030218",Other,,
2625,1000998,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S030218",Other,,
2626,1000999,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S030218",Other,,
2627,1001000,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S030218",Other,,
2628,1001001,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S030218",Other,,
2629,1001002,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S030218",Other,,
2630,1001003,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S030218",Other,,
2631,1001004,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S030218",Other,,
2632,1001005,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S030218",Other,,
2633,1001587,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S030218,Other,,
2634,1001588,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S030218",Other,,
2635,1001589,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S030218",Other,,
2636,1001590,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S030218",Other,,
2637,1003457,1,3,,103348651,6197,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S030218,Other,,
2638,1003458,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2639,1003459,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S030218",Other,,
2640,1003460,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S030218",Other,,
2641,1003461,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2642,1003462,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S030218",Other,,
2643,1003463,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S030218",Other,,
2644,1003464,1,3,,103348651,6197,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S030218",Other,,
2645,1038236,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/5,Other,,
2646,1038237,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/5,Other,,
2647,1038238,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/5,Other,,
2648,1038239,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/5,Other,,
2649,1038240,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/5,Other,,
2650,1038241,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/6,Other,,
2651,1038242,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/6,Other,,
2652,1038243,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/6,Other,,
2653,1038244,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/6,Other,,
2654,1038245,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/6,Other,,
2655,1038246,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/7,Other,,
2656,1038247,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/7,Other,,
2657,1038248,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/7,Other,,
2658,1038249,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/7,Other,,
2659,1038250,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/7,Other,,
2660,1038251,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/8,Other,,
2661,1038252,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/8,Other,,
2662,1038253,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/8,Other,,
2663,1038254,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/8,Other,,
2664,1038255,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/8,Other,,
2665,1040403,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/9,Other,,
2666,1040404,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/9,Other,,
2667,1040405,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/9,Other,,
2668,1040406,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/9,Other,,
2669,1040407,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/9,Other,,
2670,1040408,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/10,Other,,
2671,1040409,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/10,Other,,
2672,1040410,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/10,Other,,
2673,1040411,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/10,Other,,
2674,1040412,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/10,Other,,
2675,1040413,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/11,Other,,
2676,1040414,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/11,Other,,
2677,1040415,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/11,Other,,
2678,1040416,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/11,Other,,
2679,1041084,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/11,Other,,
2680,1041085,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/12,Other,,
2681,1041086,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/12,Other,,
2682,1041087,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/12,Other,,
2683,1041088,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/12,Other,,
2684,1041089,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/12,Other,,
2685,1041090,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/13,Other,,
2686,1041091,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/13,Other,,
2687,1041092,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/13,Other,,
2688,1041093,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/13,Other,,
2689,1041094,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/13,Other,,
2690,1041095,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/14,Other,,
2691,1041096,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/14,Other,,
2692,1041097,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/14,Other,,
2693,1041098,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/14,Other,,
2694,1041099,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/14,Other,,
2695,1041100,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/15,Other,,
2696,1041101,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/15,Other,,
2697,1041102,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/15,Other,,
2698,1041103,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/15,Other,,
2699,1041104,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/15,Other,,
2700,1041105,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 454/16,Other,,
2701,1041106,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 454/16,Other,,
2702,1041107,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 454/16,Other,,
2703,1041108,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 454/16,Other,,
2704,1041109,1,2,,103348651,6197,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 454/16,Other,,
2705,1053197,1,1,,103076162,6197,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2706,1086297,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay,Other,,
2707,1086298,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay,Other,,
2708,1086299,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay,Other,,
2709,1086300,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay,Other,,
2710,1086301,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay,Other,,
2711,1086917,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
2712,1086918,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
2713,1086919,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
2714,1086920,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
2715,1086921,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
2716,1090228,1,1,,103348651,6197,Active,,,,,Inhibition of cell growth in Zygosaccharomyces bailii at 50 ug/mL,Other,15969495.0,
2717,1095098,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger at 100 ug/ml after 96 hr,Other,,
2718,1095099,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger at 10 ug/ml after 96 hr,Other,,
2719,1095100,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger at 50 ug/ml after 96 hr,Other,,
2720,1095101,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus flavus at 100 ug/ml after 96 hr,Other,,
2721,1095102,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus flavus at 50 ug/ml after 96 hr,Other,,
2722,1095103,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus flavus at 10 ug/ml after 96 hr,Other,,
2723,1097337,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 after 24 to 48 hr by two-fold serial dilution method,Other,,
2724,1097338,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum ATCC 16417 after 24 to 48 hr by two-fold serial dilution method,Other,,
2725,1097339,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas phaseolicola GSPB 2828 after 24 to 48 hr by two-fold serial dilution method,Other,,
2726,1097340,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas fluorescens S 97 after 24 to 48 hr by two-fold serial dilution method,Other,,
2727,1097341,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Streptococcus pyogenes ATCC 19615 after 24 to 48 hr by two-fold serial dilution method,Other,,
2728,1097342,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 to 48 hr by two-fold serial dilution method,Other,,
2729,1097343,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 282 at 100 ug/ml after 48 hr by agar diffusion method,Other,,
2730,1097344,1,2,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum ATCC 16417 at 100 ug/ml after 48 hr by agar diffusion method,Other,,
2731,1097345,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas fluorescens S 97 at 100 ug/ml after 24 hr by agar diffusion method,Other,,
2732,1097346,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Streptococcus pyogenes ATCC 19615 at 100 ug/ml after 24 hr by agar diffusion method,Other,,
2733,1097347,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Pseudomonas phaseolicola GSPB 2828 at 100 ug/ml after 24 hr by agar diffusion method,Other,,
2734,1097348,1,2,,103348651,6197,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 at 100 ug/ml after 24 hr by agar diffusion method,Other,,
2735,1106341,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus assessed as growth inhibition after 24 to 48 hr by two-fold serial dilution method,Other,,
2736,1106342,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum assessed as growth inhibition after 24 to 48 hr by two-fold serial dilution method,Other,,
2737,1106347,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Aspergillus fumigatus assessed as diameter of growth inhibition zone at 1 mg/ml after 48 days by agar diffusion method,Other,,
2738,1106348,1,2,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Fusarium oxysporum assessed as diameter of growth inhibition zone at 1 mg/ml after 48 days by agar diffusion method,Other,,
2739,1112104,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Microbotryum violaceum by agar diffusion test,Other,22233864.0,
2740,1112105,1,1,,103348651,6197,Unspecified,,,,,Antialgal activity against 'Chlorella' fusca by agar diffusion test,Other,22233864.0,
2741,1112106,1,1,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Escherichia coli by agar diffusion test,Other,22233864.0,
2742,1112107,1,1,,103348651,6197,Unspecified,,,,,Antimicrobial activity against Bacillus megaterium by agar diffusion test,Other,22233864.0,
2743,1113004,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum f. sp. melongenae assessed as inhibition of mycelial growth,Other,23360202.0,
2744,1113005,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium oxysporum f. sp. cucumerinum assessed as inhibition of mycelial growth,Other,23360202.0,
2745,1113006,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Rhizoctonia solani assessed as inhibition of mycelial growth,Other,23360202.0,
2746,1113007,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Dothiorella gregaria assessed as inhibition of mycelial growth,Other,23360202.0,
2747,1113008,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Fusarium graminearum assessed as inhibition of mycelial growth,Other,23360202.0,
2748,1113009,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Valsa mali assessed as inhibition of mycelial growth,Other,23360202.0,
2749,1113010,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Magnaporthe grisea assessed as inhibition of mycelial growth,Other,23360202.0,
2750,1116277,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay,Other,,
2751,1116278,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay,Other,,
2752,1116279,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay,Other,,
2753,1116280,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay,Other,,
2754,1116281,1,2,,103348651,6197,Unspecified,,,,,Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay,Other,,
2755,1116282,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
2756,1116283,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
2757,1116284,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
2758,1116285,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
2759,1116286,1,2,,103348651,6197,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
2760,1117298,1,2,,170466349,6197,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2761,1117304,1,2,,170466349,6197,Inactive,,,6.3096,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2762,1117305,1,2,,170466349,6197,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2763,1117310,1,1,,170466349,6197,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2764,1117312,1,1,,170466349,6197,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2765,1117314,1,1,,170466349,6197,Inactive,,,6.30957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2766,1117324,1,1,,170466349,6197,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
2767,1117326,1,1,,170466349,6197,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2768,1117328,1,1,,170466349,6197,Inactive,,,,,human p70S6K1 kinase inhibition-screen,Screening,,
2769,1117329,1,1,,170466349,6197,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2770,1117336,1,1,,170466349,6197,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2771,1117337,1,1,,170466349,6197,Active,,,1.1486,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
2772,1117340,1,1,,170466349,6197,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2773,1117341,1,1,,170466349,6197,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2774,1117342,1,1,,170466349,6197,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2775,1117343,1,1,,170466349,6197,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2776,1117346,1,1,,170466349,6197,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2777,1117347,1,1,,170466349,6197,Active,,,0.5421,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
2778,1117349,1,1,,170466349,6197,Inactive,,,10.0,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
2779,1117350,1,1,,170466349,6197,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
2780,1117351,1,1,,170466349,6197,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
2781,1117353,1,1,,170466349,6197,Inactive,,,,,human KDR kinase inhibition-screen,Screening,,
2782,1117354,1,1,,170466349,6197,Inactive,,,,,human JAK2 kinase inhibition-screen,Screening,,
2783,1117355,1,1,,170466349,6197,Inactive,,,,,human GSK3B kinase inhibition-screen,Screening,,
2784,1117356,1,1,,170466349,6197,Inactive,,,,,human FLT3 kinase inhibition-screen,Screening,,
2785,1151304,1,3,,103348651,6197,Active,462333.0,3297.0,,,Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis,Other,24746225.0,
2786,1158055,1,1,,103348651,6197,Active,,,,,Antimicrobial activity against Saccharomyces cerevisiae assessed as compound level causing less than 2% growth after 16 hrs by serial dilution method,Other,24856903.0,
2787,1158056,1,1,,103348651,6197,Active,,,0.04,IC50,Antimicrobial activity against Saccharomyces cerevisiae after 16 hrs by serial dilution method,Confirmatory,24856903.0,
2788,1159509,1,1,,144208356,6197,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2789,1159509,1,1,,144213954,6197,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2790,1159509,1,1,,170466349,6197,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2791,1159515,1,1,,144208356,6197,Inconclusive,,,54.6386,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2792,1159515,1,1,,144213954,6197,Inconclusive,,,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2793,1159515,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2794,1159516,1,1,,144208356,6197,Inconclusive,119611100.0,22926.0,43.401,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2795,1159516,1,1,,144213954,6197,Inconclusive,119611100.0,22926.0,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2796,1159516,1,1,,170466349,6197,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2797,1159517,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2798,1159517,1,1,,144213954,6197,Inconclusive,,,42.8681,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2799,1159517,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2800,1159518,1,1,,144208356,6197,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2801,1159518,1,1,,144213954,6197,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2802,1159518,1,1,,170466349,6197,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2803,1159519,1,1,,144208356,6197,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2804,1159519,1,1,,144213954,6197,Inconclusive,119611100.0,22926.0,3.6392800000000003,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2805,1159519,1,1,,170466349,6197,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2806,1159520,1,1,,144208356,6197,Inconclusive,,,0.4826,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2807,1159520,1,1,,144213954,6197,Inconclusive,,,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2808,1159520,1,1,,170466349,6197,Inconclusive,,,0.1679,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2809,1159521,1,1,,144208356,6197,Active,15928672.0,19885.0,0.3834,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2810,1159521,1,1,,144213954,6197,Active,15928672.0,19885.0,0.1369,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2811,1159521,1,1,,170466349,6197,Active,15928672.0,19885.0,0.2371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2812,1159523,1,1,,144208356,6197,Active,15928672.0,19885.0,0.19965,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2813,1159523,1,1,,144213954,6197,Inconclusive,15928672.0,19885.0,0.172289,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2814,1159523,1,1,,170466349,6197,Inconclusive,15928672.0,19885.0,0.155454,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2815,1159524,1,1,,56463698,6197,Inconclusive,,,2.2387,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2816,1159525,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2817,1159525,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2818,1159525,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2819,1159526,1,1,,144208356,6197,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2820,1159526,1,1,,144213954,6197,Inconclusive,119627033.0,3725.0,3.0896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2821,1159526,1,1,,170466349,6197,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2822,1159527,1,1,,144208356,6197,Inconclusive,325495497.0,6256.0,0.2175,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2823,1159527,1,1,,144213954,6197,Inconclusive,325495497.0,6256.0,0.2187,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2824,1159527,1,1,,170466349,6197,Inconclusive,325495497.0,6256.0,0.1693,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2825,1159528,1,1,,144208356,6197,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2826,1159528,1,1,,144213954,6197,Inconclusive,119627033.0,3725.0,3.67195,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2827,1159528,1,1,,170466349,6197,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2828,1159529,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2829,1159529,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2830,1159529,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2831,1159531,1,1,,144208356,6197,Inconclusive,325495497.0,6256.0,0.34474699999999997,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2832,1159531,1,1,,144213954,6197,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2833,1159531,1,1,,170466349,6197,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2834,1159550,3,1,,252401204,6197,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2835,1159551,1,1,,144208356,6197,Inconclusive,,,1.5262,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2836,1159551,1,1,,144213954,6197,Inconclusive,,,1.5355,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2837,1159551,1,1,,170466349,6197,Inconclusive,,,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2838,1159552,1,1,,144208356,6197,Active,325495463.0,5914.0,0.4301,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2839,1159552,1,1,,144213954,6197,Active,325495463.0,5914.0,0.3857,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2840,1159552,1,1,,170466349,6197,Active,325495463.0,5914.0,0.1883,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2841,1159553,2,1,,144208356,6197,Inconclusive,325495463.0,5914.0,0.0963,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2842,1159553,2,1,,144213954,6197,Inconclusive,325495463.0,5914.0,0.0611,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2843,1159553,2,1,,170466349,6197,Inconclusive,325495463.0,5914.0,0.0668,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2844,1159555,1,1,,144208356,6197,Active,325495463.0,5914.0,0.328802,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2845,1159555,1,1,,144213954,6197,Active,325495463.0,5914.0,0.385708,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2846,1159555,1,1,,170466349,6197,Active,325495463.0,5914.0,0.228175,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2847,1159580,2,1,,268734878,6197,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2848,1159585,1,2,,307068770,6197,Inactive,124801388.0,812762.0,,CDPK1_IC50_uM,Biochemical screen of P. falciparum CDPK1,Confirmatory,26934697.0,
2849,1159586,1,2,,307068770,6197,Inactive,124513486.0,813740.0,,PK6_IC50_uM,Biochemical screen of P. falciparum PK6,Confirmatory,26934697.0,
2850,1159587,1,2,,307068770,6197,Inactive,124801229.0,812721.0,,PK7_IC50_uM,Biochemical screen of P. falciparum PK7,Confirmatory,26934697.0,
2851,1159588,1,2,,307068770,6197,Inactive,124511890.0,2655116.0,,CDPK4_IC50_uM,Biochemical screen of P. falciparum CDPK4,Confirmatory,26934697.0,
2852,1159589,1,2,,307068770,6197,Inactive,124803797.0,810694.0,,,Biochemical screen of P. falciparum MAPK2,Other,26934697.0,
2853,1159606,1,1,,56463698,6197,Active,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2854,1159607,2,1,,312596275,6197,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2855,1159614,1,2,,170466349,6197,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2856,1183897,1,1,,103348651,6197,Inactive,,,,,Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 25 uM after 2 to 5 hrs by inverse MTT assay,Other,25028062.0,
2857,1183898,1,1,,103348651,6197,Inactive,,,,,Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 2 to 5 hrs by inverse MTT assay,Other,25028062.0,
2858,1183903,1,1,,103348651,6197,Active,,,,,Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay,Other,25028062.0,
2859,1183904,1,1,,103348651,6197,Active,,,,,Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay,Other,25028062.0,
2860,1204659,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus niger assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method,Other,25978960.0,
2861,1204660,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method,Other,25978960.0,
2862,1204661,1,1,,103348651,6197,Unspecified,,,,,Antifungal activity against Aspergillus terreus assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method,Other,25978960.0,
2863,1204991,1,1,,103348651,6197,Active,,,,,Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay,Other,25667960.0,
2864,1204994,1,1,,103348651,6197,Inactive,,,,,"Inhibition of protein synthesis in carrageenan-induced mechanical inflammatory hyperalgesia male C57BL/6 mouse model assessed as inhibition of TNF production in inflamed tissue at 20 mg/kg, sc pretreated 1 hrs after carrageenan challenge and measured after 3 hrs by ELISA",Other,25667960.0,
2865,1204995,1,1,,103348651,6197,Active,,,,,"Inhibition of protein synthesis in carrageenan-induced mechanical inflammatory hyperalgesia male C57BL/6 mouse model assessed as inhibition of IL-1beta production in inflamed tissue at 20 mg/kg, sc pretreated 1 hrs after carrageenan challenge and measured after 3 hrs by ELISA",Other,25667960.0,
2866,1224824,1,1,,174007022,6197,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2867,1224825,1,1,,174007022,6197,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2868,1224834,3,1,,144208356,6197,Active,,,0.4301,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2869,1224834,3,1,,144213954,6197,Active,,,0.1536,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2870,1224834,3,1,,170466349,6197,Active,,,0.266,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2871,1224835,1,1,,144208356,6197,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2872,1224835,1,1,,144213954,6197,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2873,1224835,1,1,,170466349,6197,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2874,1224836,1,1,,144208356,6197,Inconclusive,,,1.3602,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2875,1224836,1,1,,144213954,6197,Active,,,0.9689,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2876,1224836,1,1,,170466349,6197,Inconclusive,,,0.5308,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2877,1224837,1,1,,144208356,6197,Active,,,0.7649,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2878,1224837,1,1,,144213954,6197,Active,,,0.6113,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2879,1224837,1,1,,170466349,6197,Inconclusive,,,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2880,1224838,1,1,,144208356,6197,Active,66775687.0,9970.0,0.2419,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2881,1224838,1,1,,144213954,6197,Active,66775687.0,9970.0,0.2731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2882,1224838,1,1,,170466349,6197,Active,66775687.0,9970.0,0.5956,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2883,1224839,1,1,,144208356,6197,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2884,1224839,1,1,,144213954,6197,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2885,1224839,1,1,,170466349,6197,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2886,1224840,3,1,,144208356,6197,Inconclusive,,,0.4301,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2887,1224840,3,1,,144213954,6197,Inconclusive,,,0.1933,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2888,1224840,3,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2889,1224841,3,1,,144208356,6197,Active,325495545.0,2101.0,0.6817,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2890,1224841,3,1,,144213954,6197,Active,325495545.0,2101.0,0.4328,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2891,1224841,3,1,,170466349,6197,Active,325495545.0,2101.0,0.5308,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2892,1224842,3,1,,144208356,6197,Inactive,325495545.0,2101.0,0.6817,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2893,1224842,3,1,,144213954,6197,Inactive,325495545.0,2101.0,0.4328,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2894,1224842,3,1,,170466349,6197,Inactive,325495545.0,2101.0,0.4731,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2895,1224843,1,1,,144208356,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2896,1224843,1,1,,144213954,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2897,1224843,1,1,,170466349,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2898,1224844,1,1,,144208356,6197,Inconclusive,,,0.3073,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2899,1224844,1,1,,144213954,6197,Inconclusive,,,0.5494,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2900,1224844,1,1,,170466349,6197,Active,,,0.379,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2901,1224845,1,1,,144208356,6197,Inconclusive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2902,1224845,1,1,,144213954,6197,Inconclusive,344243002.0,100757539.0,22.5473,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2903,1224845,1,1,,170466349,6197,Inconclusive,344243002.0,100757539.0,3.4827,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2904,1224846,1,1,,144208356,6197,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2905,1224846,1,1,,144213954,6197,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2906,1224846,1,1,,170466349,6197,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2907,1224847,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2908,1224847,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2909,1224847,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2910,1224848,3,1,,144208356,6197,Active,325495545.0,2101.0,0.6817,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2911,1224848,3,1,,144213954,6197,Active,325495545.0,2101.0,0.5448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2912,1224848,3,1,,170466349,6197,Active,325495545.0,2101.0,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2913,1224849,3,1,,144208356,6197,Inactive,325495545.0,2101.0,0.7649,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2914,1224849,3,1,,144213954,6197,Inactive,325495545.0,2101.0,0.5448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2915,1224849,3,1,,170466349,6197,Inactive,325495545.0,2101.0,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2916,1224857,2,1,,170466349,6197,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2917,1224857,2,1,,174007022,6197,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2918,1224859,2,1,,170466349,6197,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2919,1224859,2,1,,174007022,6197,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2920,1224863,1,1,,316919055,6197,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2921,1224865,1,2,,56463698,6197,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2922,1224867,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2923,1224867,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2924,1224867,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2925,1224868,1,1,,144208356,6197,Active,,,0.3868,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2926,1224868,1,1,,144213954,6197,Active,,,0.2187,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2927,1224868,1,1,,170466349,6197,Active,,,0.1693,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2928,1224869,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2929,1224869,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2930,1224869,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2931,1224870,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2932,1224870,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2933,1224870,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2934,1224871,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2935,1224871,1,1,,144213954,6197,Active,,,19.4938,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2936,1224871,1,1,,170466349,6197,Inconclusive,,,3.0107,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2937,1224872,1,1,,144208356,6197,Inconclusive,,,0.6131,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2938,1224872,1,1,,144213954,6197,Inconclusive,,,0.309,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2939,1224872,1,1,,170466349,6197,Inconclusive,,,0.3378,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2940,1224873,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2941,1224873,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2942,1224873,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2943,1224874,1,1,,144208356,6197,Active,,,0.3868,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2944,1224874,1,1,,144213954,6197,Active,,,0.2454,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2945,1224874,1,1,,170466349,6197,Active,,,0.1693,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2946,1224875,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2947,1224875,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2948,1224875,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2949,1224876,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2950,1224876,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2951,1224876,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2952,1224877,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2953,1224877,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2954,1224877,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2955,1224878,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2956,1224878,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2957,1224878,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2958,1224879,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2959,1224879,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2960,1224879,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2961,1224880,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2962,1224880,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2963,1224880,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2964,1224881,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2965,1224881,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2966,1224881,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2967,1224882,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2968,1224882,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2969,1224882,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2970,1224883,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2971,1224883,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2972,1224883,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2973,1224884,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2974,1224884,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2975,1224884,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2976,1224885,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2977,1224885,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2978,1224885,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2979,1224886,1,1,,144208356,6197,Active,,,0.434,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2980,1224886,1,1,,144213954,6197,Active,,,0.2454,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2981,1224886,1,1,,170466349,6197,Active,,,0.1693,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2982,1224887,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2983,1224887,1,1,,144213954,6197,Inconclusive,,,2.7536,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2984,1224887,1,1,,170466349,6197,Inconclusive,,,0.4253,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2985,1224888,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2986,1224888,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2987,1224888,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2988,1224889,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2989,1224889,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2990,1224889,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2991,1224890,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2992,1224890,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2993,1224890,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2994,1224892,1,1,,144208356,6197,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2995,1224892,1,1,,144213954,6197,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2996,1224892,1,1,,170466349,6197,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2997,1224893,1,1,,144208356,6197,Active,66775687.0,9970.0,0.293045,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2998,1224893,1,1,,144213954,6197,Inconclusive,66775687.0,9970.0,0.324533,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2999,1224893,1,1,,170466349,6197,Inconclusive,66775687.0,9970.0,0.361632,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3000,1224894,1,1,,144208356,6197,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3001,1224894,1,1,,144213954,6197,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3002,1224894,1,1,,170466349,6197,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3003,1224895,1,1,,144208356,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3004,1224895,1,1,,144213954,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3005,1224895,1,1,,170466349,6197,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3006,1224896,1,1,,144208356,6197,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3007,1224896,1,1,,144213954,6197,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3008,1224896,1,1,,170466349,6197,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3009,1248173,1,1,,103348651,6197,Active,,,0.26,IC50,Cytotoxicity against mouse 3T3 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26381063.0,
3010,1259241,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3011,1259241,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3012,1259241,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3013,1259242,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3014,1259242,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3015,1259242,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3016,1259243,1,1,,144208356,6197,Active,124375976.0,367.0,0.7649,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3017,1259243,1,1,,144213954,6197,Active,124375976.0,367.0,0.4856,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3018,1259243,1,1,,170466349,6197,Active,124375976.0,367.0,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3019,1259244,1,1,,144208356,6197,Active,348019627.0,2099.0,0.7649,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3020,1259244,1,1,,144213954,6197,Active,348019627.0,2099.0,0.3064,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3021,1259244,1,1,,170466349,6197,Active,348019627.0,2099.0,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3022,1259247,1,1,,144208356,6197,Active,124375976.0,367.0,0.708383,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3023,1259247,1,1,,144213954,6197,Active,124375976.0,367.0,0.560736,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3024,1259247,1,1,,170466349,6197,Active,124375976.0,367.0,0.390482,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3025,1259248,1,1,,144208356,6197,Active,348019627.0,2099.0,0.681713,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3026,1259248,1,1,,144213954,6197,Active,348019627.0,2099.0,0.629156,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3027,1259248,1,1,,170466349,6197,Active,348019627.0,2099.0,0.43812799999999996,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3028,1259252,1,1,,174007022,6197,Active,169655958.0,,0.4176,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3029,1259253,1,1,,174007022,6197,Active,169655958.0,,0.2348,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3030,1259255,1,1,,174007022,6197,Active,169655958.0,,0.1482,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3031,1259256,1,1,,174007022,6197,Active,169655958.0,,0.1321,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3032,1259310,1,1,,333472111,6197,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3033,1259310,1,1,,333493961,6197,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3034,1259310,1,1,,333494036,6197,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3035,1259310,1,1,,333494333,6197,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3036,1259313,1,1,,56463698,6197,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3037,1259318,1,1,,103076162,6197,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3038,1259332,1,1,,56463698,6197,Active,,,0.39299999999999996,AC50_uM,7124-01: Inhibition of CD40 signaling in B cell lineage,Other,,
3039,1259333,1,1,,56463698,6197,Inactive,,,20.0,AC50_uM,"7124-04: Celltiter Glo, Cytotoxicity assay",Other,,
3040,1259334,1,1,,56463698,6197,Active,,,0.19899999999999998,AC50_uM,"7124-02: inhibition of TNFa signaling in B cell lineage, counterscreen",Other,,
3041,1259344,1,1,,144207129,6197,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3042,1259364,1,1,,144208356,6197,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3043,1259364,1,1,,144213954,6197,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3044,1259364,1,1,,170466349,6197,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3045,1259365,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3046,1259365,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3047,1259365,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3048,1259366,1,1,,144208356,6197,Active,,,2.1558,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3049,1259366,1,1,,144213954,6197,Inconclusive,,,6.1131,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3050,1259366,1,1,,170466349,6197,Inconclusive,,,3.3491,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3051,1259367,1,1,,144208356,6197,Active,,,0.136,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3052,1259367,1,1,,144213954,6197,Active,,,0.9689,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3053,1259367,1,1,,170466349,6197,Inconclusive,,,1.6785,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3054,1259368,1,1,,144208356,6197,Inactive,109731339.0,2737.0,0.0858,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3055,1259368,1,1,,144213954,6197,Inactive,109731339.0,2737.0,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3056,1259368,1,1,,170466349,6197,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3057,1259369,1,1,,144208356,6197,Active,109731339.0,2737.0,0.0121,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3058,1259369,1,1,,144213954,6197,Active,109731339.0,2737.0,0.0486,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3059,1259369,1,1,,170466349,6197,Active,109731339.0,2737.0,0.1496,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3060,1259377,1,1,,144208356,6197,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3061,1259377,1,1,,144213954,6197,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3062,1259377,1,1,,170466349,6197,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3063,1259378,1,1,,144208356,6197,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3064,1259378,1,1,,144213954,6197,Inconclusive,54288833.0,2100.0,0.7696,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3065,1259378,1,1,,170466349,6197,Inconclusive,54288833.0,2100.0,1.1883,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3066,1259379,1,1,,144208356,6197,Inconclusive,,,0.7649,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3067,1259379,1,1,,144213954,6197,Inconclusive,,,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3068,1259379,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3069,1259380,1,1,,144208356,6197,Inconclusive,,,0.0682,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3070,1259380,1,1,,144213954,6197,Inconclusive,,,0.0863,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3071,1259380,1,1,,170466349,6197,Inconclusive,,,0.0335,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3072,1259381,1,1,,144208356,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3073,1259381,1,1,,144213954,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3074,1259381,1,1,,170466349,6197,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3075,1259382,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3076,1259382,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3077,1259382,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3078,1259383,1,1,,144208356,6197,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3079,1259383,1,1,,144213954,6197,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3080,1259383,1,1,,170466349,6197,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3081,1259384,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3082,1259384,1,1,,144213954,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3083,1259384,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3084,1259385,1,1,,144208356,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3085,1259385,1,1,,144213954,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3086,1259385,1,1,,170466349,6197,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3087,1259386,1,1,,144208356,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3088,1259386,1,1,,144213954,6197,Inconclusive,,,9.6885,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3089,1259386,1,1,,170466349,6197,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3090,1259387,1,1,,144208356,6197,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3091,1259387,1,1,,144213954,6197,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3092,1259387,1,1,,170466349,6197,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3093,1259388,1,1,,144208356,6197,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3094,1259388,1,1,,144213954,6197,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3095,1259388,1,1,,170466349,6197,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3096,1259389,1,1,,124637726,6197,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3097,1259390,1,1,,144208356,6197,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3098,1259390,1,1,,144213954,6197,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3099,1259390,1,1,,170466349,6197,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3100,1259391,1,1,,144208356,6197,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3101,1259391,1,1,,144213954,6197,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3102,1259391,1,1,,170466349,6197,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3103,1259392,1,1,,144208356,6197,Active,109731339.0,2737.0,0.0171239,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3104,1259392,1,1,,144213954,6197,Inconclusive,109731339.0,2737.0,0.06113060000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3105,1259392,1,1,,170466349,6197,Active,109731339.0,2737.0,0.08095939999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3106,1259393,1,1,,144208356,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3107,1259393,1,1,,144213954,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3108,1259393,1,1,,170466349,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3109,1259394,1,1,,144208356,6197,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3110,1259394,1,1,,144213954,6197,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3111,1259394,1,1,,170466349,6197,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3112,1259395,1,1,,144208356,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3113,1259395,1,1,,144213954,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3114,1259395,1,1,,170466349,6197,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3115,1259396,1,1,,144208356,6197,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3116,1259396,1,1,,144213954,6197,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3117,1259396,1,1,,170466349,6197,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3118,1259400,1,1,,170466349,6197,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3119,1259401,1,1,,144208356,6197,Inconclusive,325495545.0,2101.0,0.607578,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3120,1259401,1,1,,144213954,6197,Inconclusive,325495545.0,2101.0,0.51435,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3121,1259401,1,1,,170466349,6197,Inconclusive,325495545.0,2101.0,0.455268,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3122,1259402,1,1,,144208356,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3123,1259402,1,1,,144213954,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3124,1259402,1,1,,170466349,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3125,1259403,1,1,,144208356,6197,Inconclusive,325495545.0,2101.0,0.643579,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3126,1259403,1,1,,144213954,6197,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3127,1259403,1,1,,170466349,6197,Inconclusive,325495545.0,2101.0,0.707838,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3128,1259404,1,1,,144208356,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3129,1259404,1,1,,144213954,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3130,1259404,1,1,,170466349,6197,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3131,1259407,1,1,,363898887,6197,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3132,1259408,1,1,,363894942,6197,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
3133,1259415,1,1,,103076162,6197,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3134,1259416,1,2,,340085975,6197,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3135,1259416,1,2,,375171955,6197,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3136,1259421,1,1,,340085975,6197,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3137,1259421,1,1,,375171955,6197,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3138,1259423,1,2,,354813539,6197,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3139,1259423,1,2,,354959651,6197,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
